Method of producing substituted vinylcephalosporins

专利摘要:
3-[(Z)-1-Propen-1-yl]-7-acylamido cephalosporins in which the 7-acyl group is phenylglycyl or substituted phenylglycyl are orally active antibiotics against Gram+ and Gram- bacteria.
公开号:SU1407400A3
申请号:SU843698551
申请日:1984-01-27
公开日:1988-06-30
发明作者:Абе Есио；Наито Такаюки；Окумура Дзюн；Хоси Хидеаки；Абураки Симпей
申请人:Бристоль-Мейерз Компани (Фирма)；
IPC主号:

专利说明:

n-R -ri-R-CgHj-CH (NHR)) - WHHs.
oh-ns sleep,
1l1 - ((cooR)
where R is H, amino-protecting group -. tert-butoxycarbonyl; R, - H, OH, halogen, lower alkyl; R is H or OH; R - H, lower alkyl, aralkyl, lower alkoxy C (lower) alkyl, R4-H OR ester group, which have antimicrobial activity and
Or, P-Rj-M-RrCftHs-CHfNHRVcfOVNH
where and R indicated above, in the environment; by mixing an organic solvent in water in the presence of aqueous alkali at room temperature, the resulting phosphoranyl product is treated under anhydrous conditions at room temperature with a carbonyl compound of the formula 0, where
can be used in medicine. I The purpose of the invention is to create compounds of the indicated class with better properties. Obtaining compounds CC lead from triphenylphosphine and compounds of the formula
-N-c (coofl4) -c-aH, i3
SI-8 SN
g
WITH
F has the indicated values, c after
R
if necessary, by removing the amino-protecting or ester group and isolating the desired product. Testing ECs show that they are active against Gram-positive and Gram-negative, as well as anaerobic bacteria. Table 8
4ib
 S
; The invention relates to the field of | obtaining new substituted vinyl cephiopochoophodes of the general formula:
C3iCONHn-G 1
° COOR4
iraR
where R is hydrogen or amino protective
a group such as tert -booxycarbonyl; K - hydrogen, hydroxyl, halogen
or lower alkoxy; R is hydrogen or hydroxyl; RJ is C-C-alkyl or C, -C-aralkyl; R - hydrogen shsh ester
Group,
with the Z-configuration relative to the ecocline double bond, having antimicrobial activity.

The aim of the invention is to develop, on the basis of known methods, a method of producing new compounds with valuable pharmacological properties.
Example 1. 3-hydroxymethyl-7-phenylacetamido-β-3-cephem-4-carboxylic acid benzhydryl ester (link 1),
Sodium salt of 7-phenylacetamido cephalosporic acid (5.g, 12.1 mmol) is added to the transportable suspension of phosphate JHoro buffer (pH 7, 162.5 ml) and dry wheat bran (20, g) at room temperature. in the form of one portion. The reaction proceeds (HPLC) until hydrolysis is complete (5 hours). The suspension is filtered to remove wheat bran, and the filtrate is cooled to 5-10 ° C dp of extractive etheration. 32 ml of chloride are added to the cooled solution methylene and then 24 ppm of a 0.5 M solution of diphenyldiazomethane in methylene chloride. Then the pH of the mixture is adjusted to 3.0 with 28% phosphoric acid. After 1 h, the reaction mixture is allowed to rise until. 56 ml of heptane formed crystalline The cue product was isolated by filtration. The yield was 3.0 g (50%).
0

0
five
0
.

five
Example 2. Benzhydryl ester of 7-amino-3-chloromethyl-3-cephem-4-carboxylic acid (compound 2).
To a suspension of PC1, (8.3 g, 40 mmol) in 1000 ml of methylene chloride were added 3.2 g of pyridine (40 mmol), and the mixture was stirred at 20 ° C for 20 minutes. To this mixture was added 5.1 g of hydroxymethyl-7-phenylacetamido-3-cephem-4-carboxylic acid benzhydryl ester (1) 10 mmol with stirring at -40 ° C at a time. This mixture is stirred at 15 minutes and held at -10 until 7 hours. To the cooled solution (1-20 ° C) 10 ml of propandiol-1.3 is added, the mixture is kept at -20 ° C for 16 hours and then at room temperature. temperature for 20 minutes while stirring. The resulting solution is washed with ice water (2x20 ml) and 10 ml of a saturated aqueous solution of NaCl, dried over magnesium sulfate and concentrated in vacuo. A gummy residue (12 g) was dissolved in a mixture of chloroform and n-hexane (2: 1) and subjected to chromatographic separation using a column with 200 g of silica gel and the same solvent as eluent. The fractions containing this compound are evaporated in vacuo, the residue is triturated in n-hexane to give 2.1 g (51%) of compound 2 with an mp. 1 (with different).
IR spectrum at EVg :. 3400, 2800, 1785, 1725 cm.
The UV spectrum in ethanol is maximum at 265 nm (160).
NMR spectrum, chemical shift in DMSO-b. + CDC13, ND: 3.69 (2H, s); 4.43 (2H, s) 5.09 (1H, d, J 4.5 Hz); 5.24 (1H, d. J 4.5 Hz); 6.87 He, s); 7.3 (YUN, m).
Example 3. Be1bhidrch10 Berster of 2- (tert-butoxycarbonyl-amino) -2-para-hydroxyphenyl) acetamido - -3-chloromethyl-3-cephalane-4-carboxylic acid (compound 3).
To a mixture of 20.7 g (0.05 mol) of 7-amino-3-chloromethyl-3-cephem-4-carboxylic acid benzhydryl ester (2) and 20 g (0.075 mol) 1) -2- (tert- Butoksik arb isilamido) -2- (para-oxiphenyl) acetic acid in 500 ml of dry tetrahydrofuran (THF) is added 15.45 g (0.075 mol) of K, H-dicyclohexylcarbodiimide (DCC), the mixture is stirred at room temperature temperature in
for 2 h and evaporated to dry. The residue is dissolved in 1 L of ethyl acetate, and the insoluble dicyclohexyl urea is removed by filtration. The filtrate is washed with an aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of NaCl, dried over anhydrous sodium sulphate and the solvent evaporated. The oily residue is separated by chromatography on a column with 500 g of silica gel (Wacgel C-100U elutes with 4 l of chloroform and 6 l of a mixture of 99% chloroform and 1% methanol. The desired fractions are combined and evaporated to dryness. The oily residue is triturated with ether-isopropyl ether to give 30.6 g (92%) of compound 3.
IR spectrum on KBG, cm: 1790, 1710 1670, 1500, 1360, 1230, 1150. NMR spectrum, chemical. shift in CDCl1, ad: 1.45 (% H, s, C – CH); 3.4 (2H, brs, 2-H); 4.28 (2H, s.); . 4.86 (1H, d, 4.5 Hz, 6-H); 5.12 (iH. D, 6 Hz, CH-CO); 5.68 (1H, dd, 8 and 4.5 Hz, 7-H); 6.63 (2H, d, 9 Hz, phenyl-H); 6.93 (1H, s, CH-phenyl); 7.08 (2H, d, 9 Hz, phenyl-H G; 7.0 - 7.5 (10H, m, phenyl-H).
This oily page can be used without chromatographic purification in rtpHMepe 4.
Example 4. Benzhydryl ester of (tert-butoxycarbonyl-amino) -2- (para-hydroxy-1) acetamido - -3-iodomethyl-3-cephem-4-carboxylic acid (compound 4J.
A mixture of 26.6 g (0.04 mol). 3 t of 18 g (0.12 mol) of sodium iodide in 400 ml of acetone are stirred at room temperature for 2 hours and evaporated to dryness. The residue is extracted with 400 MP of ethyl acetate, the extract is washed with an aqueous solution of Na S O, water and a saturated aqueous solution of sodium chloride. After evaporation of the solvent, the residue was triturated with ether-isopropyl ether to give 27 g (89%) of the title compound. The ethyl acetate solution can be used directly in the next step (compound 5) without isolating compound 4.
IR spectrum on KBr, jn «ne, 1790, 1710, 1670, 1500, 1360, 1220, П50.
NMR spectrum, him. shift in CDClj, m, d: 1.47 (9H, s, C – CH j); 3.3-3.6
(2H, m, 2-H); 4.20 (2H, s, SI,); 4.89 (1H, d, 4.5 Hz, 6-H); 5.12 (1H, d, 6 Hz, CH-CO); 5.68 (1H, dd, 8 and 4.5 Hz, 7-H); 6.62 (2H, d, 9 Hz, phenyl-H); 6.92 (W, s, CH-phenyl,); 7.08 (2H, d, 9 Hz, f-N); 7-7.5 (YUN, m, phenyl-N).
Example 5. D-2- (tert-butoxycarbonyl-amino) -2- (para-oxyphenyl) acetamido | - -3- (triphenylphosphonio) methyl-3-cephem-4-carboxylic acid benzhydryl ester, iodide (compound 5) .
A mixture of 15.1 g (0.02 mol) 4 and 15.7 g (0.06 mol) of triphenylphosphine in 200 ml of ethyl acetate is stirred at room temperature for 1 h. The precipitate formed is collected by filtration to obtain 17.4 g (85.5%) of compound 5 melting at 170-180 ° C. The filtrate is concentrated to a volume of 100 ml, the concentrate is diluted with 500 ml of ether, yielding an additional yield (1.1 g) 5. The total yield of 18.5 g (91%). The total yield of compound 5 out of 2 is 74.5%. He can. be increased to 87.5% due to the elimination of purification and allocation steps, as indicated,
IR spectrum at KBG "cm aux: 1780, 1670, 1490, 1420, 1350, 1240, 1150, 1090,
NMR spectrum chemical shift in DMSO, m, d,: 1.42 (9H, s, C-CHj); 3.45 (2H, shir, s., 2-H); 5-5.4 (3N, m, 3-H and 6-H); 5.7 (W, m, 7-H); 6.63 (2H, d, 9 Hz, phenyl-H); 7.1-7.45 (12H, m, phenyl-N); 7.5-7.9 (15H, m, phenyl-H).
Calculated,%: C, 61.36; H 4.85; N 4.13; S 3.15.
CeeH NASPl
Found,%: C 61.26; H 4.82;
N 4.1-1; S 3.92,
Example 6. Benzhydryl ester) -2- (tert-butoxycarbonyl-amino) -2- (para-hydroxyphenyl) acetamido - -3- (Z) -1-propen-1-yl-3-cephem-4-carboxylic acid (compound 6).
To a solution of 1.8 g (1.77 mmol) of compound 5 in 100 ml of chloroform was added 100 ml of water, containing 2 ml (2 mmol) of 1 N, sodium hydroxide solution, and the mixture was shaken for 5 minutes. The organic layer is separated, washed with water and dried over anhydrous sodium sulphate. The chloroform solution is filtered, the filter is concentrated to 50 ml. Under reduced pressure.
Mr. pressure. To the concentrate was added 1 g of acetaldehyde, the mixture was stirred at room temperature for 2 hours and evaporated to dryness. The oily residue is purified chromatographically on a column of 50 g of silica gel (Waco-gel C-200), eluted with chloroform and a mixture of chloroform and methanol (99: 1). The desired fractions are collected and evaporated to give 318 mg (28%) of the product 6 with t, w :, 120-130 0 (with,).
IR spectrum at KBG, „, 1780, 1670, 1710, 1A90, 1360, 1210, 1150.
NMR spectrum, chem. shift in CDC1 ,, m, d,: 1.3-1.5 (12H, m, C — CH,); - 3.22 (2H, shir, si, 2H); 4.90 (1H, d, 4.5 Hz, 6-H); 5.15 (1H, tir. D ,, CH-CO); 5.5-6.1 (ЗН, m, СН - СН и. 7-Н); 6.63 (2H, d, 9 Hz, phenyl-H); 6, .91 (1H, s, CH-phenyl); 7.09 (2H, d,
9 Hz, phenyl-H); 7.2-7.5 (YUN, m, phenyl-N),
Example 7 Sodium salt of 7f- g-2-amino-2- (para-hydroxyphenyl) acetamido-3- (Z) -I-propen-1-yl-3-cephem-4-carboxylic acid, compound 7 , VMU-28100, sodium salt.
A mixture of 318 mg (0.48 mmol) of compound 6 and 2.5 ml of trifluoroacetic acid (TFA) was stirred at room temperature for 1 hour and then diluted with 50 ml of ether and 50 ml of isopropyl ether. The remainder of the yti is collected by filtration, washed
ether, 188 mg (77%) of trifluoroacetate 7, which is dissolved in 2 ml of methanol, 2 ml (2 mmol) are added to this solution. of ethyl acetate solution, dilute the mixture with 30 mp of ethyl acetate to isolate a precipitate which is collected by filtration, washed with ether and dried under vacuum over phosphorus pentoxide, to give 144 mg (73% of 6). crude compound 7, the crude product (135 mg) is dissolved in 10 ml of water, the solution is chromatographed on a column (25 mm x 100 mm) using about 20 MP of a rager PAK-500 / Cjg phase (Waters) phase, the column is eluted water and the eluate, containing the desired product, is concentrated to 5 ml, lyophilized, to obtain 93 mg (69%) of 7 dinene 7. T, pl. (gradual, decomp,). The HPLC purity rating is about 60%,
IR spectrum on KBG,
cm
1760, 1660, 1590, 1400, 1360, 1250.
UV spectrum, in phosphate buffer pH 7, nm (e): 227 (PWEP), 280 (8200),
NMR spectrum, chemical, shift in D ,, 0, ppm: 1.65 (3N, d, 6. Hz, -C-CHj); 3.21 (1H, d, 18 Hz, 2-H); 3.52 (1H, d, 18 Hz, 2-H); 5.12 (W, d ,, 4.5 Hz, 6-H); 5.68 (IH, d, 4.5 Hz, 7-H); 5.5-5.9 (1H, m, vinyl-H) | 5.95 (1H, d, 11.5 Hz, vinyl-H); 6.94 (2H, d, 8 Hz, phenyl-H); 7.36 (2H, d, 8 Hz, phenyl-H).
Example 8, 7c-D-2-Amino-2- - (parathoxyphenyl) acetamide-3- (F) - -1-pr6pen 1-yl} -3-cephem-4-carboxylic acid (compound 8, BBS-1067) .
Obtained in Example 7 Crude
Product 11.9 g of Compound 7 was dissolved in 50 ML of a mixture of 0.01 M phosphate buffer (pH 7.2) and methanol (85:15), and the solution was acidified to pH 6 with hydrochloric acid.
. (6n,). This solution is subjected to preparative high performance liquid chromatography (HPLC) (Rahr PAK-500 / C, System 500, Waters) with elution with 0.01 M phosphate buffer (pH 7.2) containing 15% methanol. The eluate is analyzed by the method IHBR, The first 4 L fractions were found to contain the cis isomer (BMU-28100), the second fraction O (l) containing the trans-isomer was collected and concentrated to 500 ml. The concentrate is acidified to pH 3 with dilute hydrochloric acid and refined on a HP-20 column (100 ml), eluting with 1 liter of water and 1 liter of 30% nbgo methanol. The latter zlyuat (about 300 ml) is concentrated to 10 ml and lyophilized to obtain 290 mg of crude trans isomer (55% purity). This material is dissolved in 100 ml.
50% methanol and treated with activated carbon. The filtrate is concentrated to a volume of 20 ml and incubated overnight at 5 ° C. This product crystallizes as colorless prisms that are collected by filtration and dried under vacuum, 129 mg, t, mp, 230 ° C (with,).
IR spectrum on KBV,

1550,
1520, 1450,
5 1760, 1680, 1590, 1390, 1350, 1240,
UV spectrum in phosphate buffer (pH 7), nm (e): 228 (13000), 292 (16900),
71407400
NMR spectrum, chemical shift in + soda, ppm: 1.89 (3N, d, 6 Hz, С С-СНз); 3.60 (2H, s, 2-H) ;. 5.13 (1H, d, 4.5 Hz, 6-H); 5.20 (1H, s, CH-CO); 5.68 (1H, d, 4.5 Hz, 7-H); 5.99 (1H, dd, 16, and 6 Hz); 6.54 (1H, d, 16 Hz); 6.98 (2H, d, 9 Hz, phenyl-H); 7.41 (2H, d, 9 Hz, phenyl-H),
II p and m, er 9. Crystalline 7 - in-2-amino- (para-hydroxyphenyl) acet-amido -3- (Z) -1-propen-1-id -3-cephem-4-carboxylic acid (compound 9, VMU-28100).
The first fraction (4 l), prepared by preparative HPLC in example 8, containing the cis isomer (VMU - 28100), is concentrated to a volume of 2 liters, the concentrate is acidified to pH 3
Found,%: C 54.15; H 5.13; N 10.30; S 8.38. C 54.19; H 5.08; N 10.42; S 8.04.
The mother liquor from the preceding crystallization is concentrated to a volume of 10 MP and treated with 20 ml of acetone. After keeping the solution in the refrigerator overnight, a crystalline precipitate is formed, which is collected by filtration and dried under vacuum over phosphorus pentoxide, weight 670 mg (90% purity, according to HPLC). Some of this stuff
15 (560 mg) is dissolved in 200 ml of 50% aqueous EH methanol, the solution is treated with 0.5 g of activated carbon and filtered. The filtrate is concentrated under reduced pressure at 40 ° C to volume with dilute hydrochloric acid, diluted with 20–20 ml and stored for 5 hours at
the thief is loaded onto a column containing 1 liter of HP-20 phase, and the column is washed. 6 liters of water until the pH of the effluent is set to 7.0. Then the column was eluted with 4 liters of 30% aqueous methanol. The eluant solution was analyzed by HPLC and the corresponding fractions were combined (about 2.5 L) and concentrated to 50 ml at a "lower temperature" under reduced pressure. A crystalline precipitate is formed. The concentrate is cooled for 2 hours, the crystalline precipitate is collected by filtration, washed with 80% aqueous acetone, then with 100% acetone, and dried in vacuo to give 4.09 g of pure crystalline desired product, with tonnes. 218-220 C (with diss.), Colorless 35 A solution of 3 g (2.95 mmol) of benzhydryl ether (N-Tt eT-6yTOKCH-carbonylamino) -2- (para-hydroxyphenyl) acetamido.-3- (triphenylphosphonio) methyl- -3-cephem-4-carboxylic acid, iodine-
cm :
prisms with a purity of 95%, as found Q yes (h) in 50 ml of chloroform, shake by analogging HPLC.
IR spectrum, at KBG, h ks 1750, 1680, 1560, 1520, 1460, 1390, 1350, 1270, 1235. „
UV spectrum in phosphate buffer (pH 7), g of saturated NaCl solution (20 MP)
with a mixture of 3 ml (3 mmol) of 1N sodium hydroxide solution and 50 ml of water at room temperature for 1 minute. Separate the organic layer after adding:
mackle
nm (s): 228 (12300), 279
From 9800).
NMR spectrum, CIM. shift in + + NaHCGj, md: 1.71 (3N, .d, 6.Hz), .-,
and washed with water (3x30 ml). To the organic solution was added 2.5 ml of 35% aqueous formaldehyde with careful transfer and cooling (C-CH); 3.27 (W, d, 18 Hz, 2-H); 3.59 per day with water. Stirring is continued.
(1H, d, 18 Hz, 2-H); 5.18 (1H, d,
4.5 Hz, 6-H); 5.22 (W, -C, SNCO);
5.73 (1H, d, 4.5 Hz, 7-H); 5.5-6.0
(1H, m,); 6.02 (1H, d, P Hz,
); 6.98 (2H, d, 9 Hz, phenyl-H);
7.41 (2H, d, 9 Hz, phenyl-H);
Calculated,%: C 54.26; H 5.06; N 10.55; S 8.05.
1 / 2H #
C e K NjOjS
within 20 min. The organic layer is separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The concentrate was placed in a silica gel column, which was zeolized with chloroform (600 ml) and 2% methanol in 800 ml of chloroform, to obtain 850 mg (45%) of the indicated compound. Thin layer chromatography (TLC); R
Found,%: C 54.15; H 5.13; N 10.30; S 8.38. C 54.19; H 5.08; N 10.42; S 8.04.
The mother liquor from the previous crystallization is concentrated to a volume of 10 MP and treated with 20 ml of acetone. After keeping the solution in the refrigerator overnight, a crystalline precipitate is formed, which is collected by filtration and dried in vacuum over phosphorus pentoxide, weight 670 mg (purity 90%, according to HPLC). Some of this stuff
(560 mg) is dissolved in 200 ml of 50% aqueous EH methanol, the solution is treated with 0.5 g of activated carbon and filtered. The filtrate is concentrated at 5 ° C. The product crystallizes, is collected by filtration, washed with acetone and dried under vacuum over PjOj, to give 227 mg of crystalline
25 BMU-28100 (98% purity, according to GHUR). By lyophilization of the uterine solution, 181 mg of BMU-28100, having a purity of 95% (HPLC), is obtained.
Example 10. Diphenyl methyl
30 ester of (tert-butyroxycarbonyl-amino) -2- (para-hydroxyphenyl) acetamido - -3-vinyl-3-cephem-4-carboxylic acid (compound 10).
35 A solution of 3 g (2.95 mmol) of benzhydryl ester (N-Tt eT-6yTOKCH-carbonylamino) -2- (para-hydroxyphenyl) acetamido.-3- (triphenylphosphonio) methyl-3-cephem-4-carbon acid, iodine
Q yes (h) in 50 ml of chloroform shake-
yes (h) in 50 ml of chloroform shake-
 saturated NaCl solution (20 mp)
with a mixture of 3 ml (3 mmol) of 1N sodium hydroxide solution and 50 ml of water at room temperature for 1 minute. The organic layer is separated and added with water (3 x 30 ml). To the organic solution is added 2.5 ml of 35% aqueous formaldehyde with careful transfer and cooling with water. Stirring is continued.
within 20 min. The organic layer is separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The concentrate was placed in a silica gel column, which was zeolized with chloroform (600 ml) and 2% methanol in 800 ml of chloroform, to obtain 850 mg (45%) of the indicated compound. Thin layer chromatography (TLC); R
1407400
0.48 (silica gel, methanol-chloroform 1:10).
Example P. 7 - p-2-Amino-2- - (pg1ra-hydroxyphenyl) acetamido-3-vinyl-3H-cephem-4-tsarboxylic acid (Compound 11, BBS-1064).
A mixture of 850 mg (1.32 mmol) of compound 10 and 5 ml of 90% aqueous trifluoro; chloroform ca 1.08 g ki
 1:10), evaporated; semi- (55%) of the indicated compound spectrum on KBr,
VI and COP
cm :
acetic acid is supplied with com-oxylate (compound Гз,, nat1780, 1680, 1500.
Example 13. Sodium-Amin-2- (p-hydroxyphenyl) acetamido - -3- | (g) -1-buten-1-yl-3-cephem-4-carb-
suction temperature for 1 hour and concentrated to approximately 1 ml in vacuo. The concentrate was triturated with 20 MP of diisopropyl ether to give 679 mg of a yellow product, which was dissolved in 3 MP of methanol and then diluted with 30 MP of water. This solution is passed through a column of HP-20 phase (50 ml), which is washed with 200 ml of a pepper and eluted with 250 mp of 30% methanol. The eluate containing the desired compound is concentrated and lyophilized to obtain 197 mg (31%) of the indicated co-g (inenia, 60% purity by HPLC evaluation,
city square 190 ° C (with decomp.). IR spectrum on KBV,
m to
1760, 1680, 1615, 1570, l520, UV spectrum in phosphate buffer
pug
SRN 7), 7 183 (14400). NMR spectrum in
km (e): 228 (13,500),
pjO, chemical shift ,, sc,
MD: 3.6 (2H, s, SCHg); 5.51 (1H, A, 5 Hz, 6-H) {5.73 (1H, d, 5 Hz, -H); 7.03 (2H, d, 8 Hz, phenyl-H); - 7.45 (2H, d, 9 Hz, phenyl-N). I Example 12. Diphenylmethyl: | fir (tert-butoxycarbonyl-amino) -2- (para-hydroxyphenyl) acetamido} -3- (2) -1-bute 1-ts-cefem-4-carboxylic acid (compound 12). ; A solution of 3 g (2.95 mmol) of the compound - 1 | si 5 in 50 MP of chloroform is mixed 4 ° with a mixture of 3.2 ml (3.2 mmol) of 1N sodium hydroxide solution and 50 ml of water, shaken at room temperature within 3 min. The organic layer was separated, washed with water (3 3 times with 30 mp) and a saturated aqueous solution of NaCl and dried over anhydrous sodium sulfate. 1.71 g (29.5 mmol) of propio-HtOBoro aldehyde was added to the solution. The mixture is stirred B | overnight at room temperature and concentrate under reduced pressure. The concentrate is loaded into a silica gel, which is eluted with li-2% 14 tanol in chloroform. The fractions are combined, which are observed by the method of those spots with Rf 0.30 (methanol
0
; chloroform ca 1.08 g ki
ten
 1:10), evaporated; semi- (55%) of the indicated compound spectrum on KBr,
VI and COP
cm :
oxylate (compound Гз,, nat1780, 1680, 1500.
Example 13. Sodium-Amin-2- (p-hydroxyphenyl) acetamido - -3- | (g) -1-buten-1-yl-3-cephem-4-carb-
5 o
five
0
salt of salt).
A solution of 1.08 g (1.61 mmol) of compound 12 in 11 ml of trifluoroacetic acid containing 1% water is kept for 1 hour at room temperature. The mixture is concentrated to a volume of about 2 ml in vacuo, the resulting syrup is triturated with approximately 20 ml of diisopropyl ether to obtain 796 mg of a yellow powder. This powder is dissolved in 3 ml of methanol, the solution is treated with 3 ml of a 0.8 M solution of sodium ethylene hexanoate in ethyl acetate to obtain a precipitate, which is filtered, washed with diisopropyl ether and dissolved in 5 ml of water. The rast-, thief is passed through a column filled with 80 ml of the PAK-500 / Cg rger phase (replaceable cartridge from Waters), which is washed with water and eluted successively with 10% methanol, 20% methanol and 30% methanol. The target fractions (monitored by HPLC) were combined, concentrated and lyophilized to obtain 118 mg (9.4%) of the title compound, an assessment of 55% purity (by HPLC); darkens when heated in a glass capillary at a temperature above 180 ° C.
IR spectrum at KBG, COP 1755, 1660, -1580.
UV spectrum in phosphate buffer (pH 73, 71 „ks them (e): 228 (10900), 278 (7200).
NMR spectrum in DO, x m. Shift, md: 0.81 (3N, t, 7.5 Hz); 1.7-2.2 (2H, m); 3.25. (2H, AB squ.); 5.01 (1H, d, 5 Hz) ;. 5.50 (W, d, 7.5 and 12 Hz); 5.58 (1H, d, 5 Hz); 5.78 (1H, 0 d, 12 Hz); 6.86 (2H, d, 8 Hz); 7.26 (2H, d, 8 Hz).
Example 14. (tert-Butoxycarbonyl-amino) -2- (p-hydroxyphenyl) acetamido-g-3- (g) -3-phen-1-propen-1-yl-3-cep-4-diphenylmethyl ester carboxylic acid (compound 14).
A solution of 3 g (2.95 mmol) of compound 5 V 50 ml of chloroform intermix 5
0
five
Wash with a mixture of 3.2 ml (3.2 mmol) of a 1 ". caustic soda solution and 50 ml of water for 1 minute. Separate the organic layer after adding a saturated solution of NaCl (20 ml), wash with water (3 times 30 ml each time) and with an aqueous solution of NaCl and dry over anhydrous sodium sulfate. To this solution, 7.2 g (30 mmol) of 50% phenylacetaldehyde are added to the solution, and the mixture is stirred overnight at room temperature. The reaction mixture was concentrated in vacuo, the concentrate was purified on a column of 75 g of silica gel using 1% methanol in chloroform as eluent to obtain 800 mg (37%) of the title compound.
TLC: Rr 0.33 (silica gel, methanol: chloroform 1:10).
IR spectrum, KVG: 1780, 1710-1680 cmH
This compound was used for the synthesis in Example 15 without further purification.
Example 15, 7 - D-2-Amino--2g (para-hydroxyphenyl) acetamido -3-t (Z) -3-phenyl-1-propan-1-yl-3-cephem-4-carboxylic acid ( compound J5, BBS-1076).
A solution of 800 mg of compound 14 in 4 ml of 90% trifluoroacetic mixture was held for 2 hours. The reaction mixture was concentrated and triturated with diisopropyl ether to obtain 490 mg of a yellow powder. A solution of the powder in 2 ml of methanol is mixed with 20 ml of water and fed to a column with HP-20 phase (50 mA), which is washed with water, 250 ml and eluted with 250 ml of 30% methanol and then 300 ml of 75% methanol. The methanol (75%) eluate is concentrated and lyophilized in 10 ml of 75% methanol and chromatographed on a column filled with 80 ml of phase (PAK-300 / C rger, j, Waters replaceable cartridge). The column was eluted with 75% methanol to obtain 158 mg (31%) of the desired product. Evaluation of purity by ZhBR - 65%. Substance darken when heated in the st: clned capillary above.
IR spectrum, KVG,, „, (6 cm: 1760,. 1680, 1600-1580, 1520,
UV spectrum in phosphate buffer
 7) m «ks (e 2vO (8900). NMR spectrum in DMSO-a + PaO (5: 1), chemical shift, MD: 4.45 (2H, d, 4 Hz)); 4 , 87 (1H, c.-CHNDj); 6.7

12
d, 9 Hz, phenyl); 6.9-7.5 (7H, m,
five
0
five
phenyl).
Prime
p 16. Diphenylmethyl
(tert-butoxycarbonyl-amino) -2- (p-hydroxyphenylacetamido) ester}} - | -3- (2) -3-methoxy-1-propen-1-yl-3- -cepheme-4-carboxylic acid (compound 16 ).
A solution of 3.0 g (2.95 mmol) of compound 5c. chloroform (100 ml) is prepared, bathed with a mixture of 2N caustic solution (1.8 ml) and 100 ml of water at the natal temperature for 5 minutes. The organic phase is separated, washed with 50 ml of water and 50 aqueous NaCl, dried and evaporated to a volume of about 10 ml. The resulting red solution of ylide is treated with 1.8 ml of methoxyacetaldehyde (15 mmol) at room temperature for 15 minutes. After evaporation of the solvent, the residue is chromatographed on a column of silica gel (100 L), eluting with toluene-ethyl acetate (3: 1 and 1: 1) to obtain the indicated compound (750 mg, .38%).
thirty
35
NMR spectrum in CDCl j + D 0, chem. shift. m, d: 1.45 (9H, s, tert.-butyl); 3.15 (ЗН, с, ОСНз); 3.27 (2H, s, 2-CH2); about 3.5 (2H, m, -CH - Ome); 4.9 (1H, d, 5.0 Hz, 6-H); 5.12 (1H, s, -CH-ND-); about 5.5 (1H, m, CH-CH .-); 5.72 (1H, d, 6-H); 6.18 (1H, d, 12 Hz, -CH-CH-CH2-); 6.65 and 7.10 (each 2H, d,); 6.90 (1H, s, -CHPh); 7.3 (Yun, s, Ph) Example 17. 7-C2-AMINO-2-Q (p-hydroxyphenyl) acetamido-3- (2) -3-methoxy-1-propen-1-yl-3-cephem-4-carboxylic acid ( compound 17, BBS-1092).
five
Compound 16 is released by trifluoroacetic acid (3 ml) at room temperature for 1 hour. By evaporation of the solvent followed by separation of the precipitate from isopropyl ether, the product trifluoroacetate is obtained, which is purified on a HP-20 column by chromatography. The column is washed with 500 ml of water and eluted with 500 ml of 30% methanol to obtain 350 mg (75%) of the desired product. Estimation of purity on GHUR-90%, so pl. 1B
0
(with,).
IR spectrum, KBG, KS 3180 1760, 1680.
 3400,
13
UV spectrum, in phosphate buffer СР 7), „„, nm (e): 228 (11500),: 279 (9400).
: NMR spectrum, chemical shift, ppm: 3.4 (3N, s, OCH); 3.40 (2H, iAB-KB, 2-CH); 4.0 (2H, m); 15.19 (1H, 4.5 Hz, 6-H); 5.25 (IE, s, -CH-ND); 5.77 (W, d, 7-H); about 5.8 (W, m., CH-CH -); 6.20 (1H, d, 11 Hz, -CH CH-CH,); 7.05 and 7.45 (each 2H, d and d,). I Example 18. Diphenylmethyl I ether (tert-butoxycarbonyl-amino) -2- (p-hydroxyphenyl) adamethamido 1 -3- ;- (g) -3-chloro-1-propen-1-sh1 -3-cephem- {- - 4-carboxylic acid / compound 1 8). I A solution of compound 5 (5 g, 4.9 mmol) in 100 ml of chloroform is treated with a mixture of 2 and a solution of caustic 1 of sodium (2.9 ml, 5.8 mmol) and water 1 (100 ml) at room temperature IB for 5 minutes. The organic phase is separated and washed with 50 ml of water and 50 ml of saturated NaCl solution. and | dried over anhydrous sulfate | sodium. The filtrate is evaporated to a volume of about 20 ml and 2.0 ml (25 mmol) of chloroacetaldehyde is added. Mixture
1) and (3.9 mmol) in 18 ml of acetone is stirred at room temperature for 1 hour. After evaporation of the solvent, the residue is dissolved in this acetate (100 ml), washed with water, an aqueous solution and an aqueous solution of NaCl, in dried and evaporated to give
10 th compound (1.02 g).
NMR spectrum in CDClj + D O, chemical mixtures ppm: 1.45 (9H, s, tert.-butyl); o lo 3.4 (2H, m, 2-CHj); about 3.8 (m); 4.90 (1H, d, .5 Hz, 6-H
15 5.14 (1H, s, -CH-ND-); 5-, 73 (1H, d 7-H); about 5.5-6.0 (1H, m, CH-CH 6.68 and 7.10 (each 2H, each d, phenyl); 6.78 (H, d, 5 Hz, 3-CH CH- ° CH 6.99 (1H, s, CHPhi); 7.3 (YUN,
20 Ph),
Example 20. Diphenylmethyl ester (tert-butoxycarbonyl but) -2- (p-hydroxyphenyl) acetamido -3-3 -1,2,3-triaz) thio-1-propene-1
25 Il 3-cephem-4-carboxylic acid (combination 20).
To a solution of 1.0 g of compound 19 (1.3 mmol) in ethyl acetate (20 ml) is added 0.27 ml of propylene oxide
stirring at room temperature (mmol) and 19 ml of 0, W solution
pe 30 min and evaporated in vacuo. The remaining syrup is chromatographed on a column of 100 g of silica gel, eluting with a mixture of toluene-ethyl acetate (3.1),
| Beam 900 mg (27%). The indicated synergy syrup is chromatographed on
. f4i f f.
1 week 18.
 NMR spectrum in CDCl ,, chemical shift, ppm: 1.45 (9H, s, tert.-butyl), about 3.3 (2H, m, 2-CH2); 3.5-4.0 (2H, m); 4.92 (1H, d, 5.0 Hz, | 6-H); 5.12 (W, s, -CH-ND-); about 5.7 (2H, m, 7-H and CH-CH2); 6.15 (W, d, 11 Hz, -3-CH CH-CH2-); 6.63 and 7.10 (each 2H, d, and d,,); 6.89. ("AND,
When releasing this substance with trifluoroacetic acid, as in the previous examples (for example, 7, 11, etc.), 7-c-amino-2- (p-hydroxyphenyl) -acetamido-3- (g) -3-chloro- 1- -propene-yl-3-cephem-4-carboxylic acid.
Etc. and measure 19. Diphenylmethyl ether (tert-butoxycarbonylmilone with C-200 silica gel (50 g). The expected product is eluted with a mixture of chloro-form-methanol (10: 1) and obtain 800 mg (83%) of the indicated compound. 40 NMR- spectrum in CDClI + HG, chemical shift, MD: 1.45 (9H, s, tert-butyl); about 3.3 (4H, .m, and -CHg-.); 4.80 (1H, d, 5.0 Hz, 6-H); 5.20 (W, s, -CH-ND-); 5.70 (W, d.
phenyl). 7-H); about 5.95 (1H,
m
CH-CH -);
50
6.68 (2H, d, HO-phenyl); 6.90 (1H, s, -CH-Phg); 7.25 (YUN, s, Ph); 7.52 (W, s, triazole-4-H).
Example 21. 7 - B-2-amino. -2- (p-hydroxyphenyl) acetamido -3-3- (W--2,2, 3-triazol-5-yl) thio-1-propen-1 -yl or 3-cephem-4-carboxylic acid (compound 21, BB5-1091).
A mixture of 800 mg of compound 20 and
But) -2- (p-hydroxyphenyl) acetamido-3- (E) -gg 2 ml of trifluoroacetic acid are incubated with 3-iodo-propen-1-yl3-3-cephemcarboxylate for 1 hour at room temperature with iic acid ( 9). and then evaporated to dryness. To the rest
A mixture of 900 mg of compound 18 was added with isopropyl ether and a yellow precipitate (600 mg) was obtained (1.8 mmol) and 590 mg of iodide.
 .
40740014.
1) and (3.9 mmol) in 18 ml of acetone is stirred at room temperature for 1 hour. After evaporation of the solvent, the residue is dissolved in ethyl acetate (100 ml), washed successively with water, aqueous solution and aqueous NaCl solution, dried and evaporated to give the indicated compound (1.02 g).
NMR spectrum in CDClj + D O, chemical shift, ppm: 1.45 (9H, s, tert.-butyl); about 3.4 (2H, m, 2-CHj); about 3.8 (2H, m); 4.90 (1H, d, .5 Hz, 6-H);
15 5.14 (1H, s, -CH-ND-); 5-, 73 (1H, d, 7-H); about 5.5-6.0 (1H, m, CH-CH -) 5 6.68 and 7.10 (each 2H, each d, HC-phenyl); 6.78 (N, d, 5 Hz, 3 -CH CH- ° CH. (-); 6.99 (1H, s, CHPhi); 7.3 (UN,
20 Ph),
Example 20. Diphenylmethyl ester of (t-butoxycarbonylamino) -2- (p-hydroxyphenyl) acetamido-3-3 (1H -1,2,3-triaz) thio-1-propen-1-
25 Il 3-cephem-4-carboxylic acid (compound 20).
0.27 ml of propylene oxide is added to a solution of 1.0 g of compound 19 (1.3 mmol) in ethyl acetate (20 ml).
(1H-1,2,3-triazol-4-yl) thiol in ethyl acetate. The mixture is stirred at room temperature for 30 minutes and evaporated under reduced pressure. Left f4i f f.
Lonke with C-200 silica gel (50 g). The target product is eluted with a mixture of chloro. form methanol (10: 1) and obtain 800 mg (83%) of the title compound. NMR spectrum in CDCl j + H G, chem. shift, MD: 1.45 (9H, s, tert-butyl); about 3.3 (4H, .m, and -CHg-.); 4.80 (1H, d, 5.0 Hz, 6-H); 5.20 (W, s, -CH-ND-); 5.70 (W, d
 7-H); about 5.95 (1H,
m
CH-CH -);
50
6.68 (2H, d, HO-phenyl); 6.90 (1H, s, -CH-Phg); 7.25 (YUN, s, Ph); 7.52 (W, s, triazole-4-H).
Example 21. 7 - B-2-amino--2- (p-hydroxyphenyl) acetamido-3-3- (W- -2,2, 3-triazol-5-yl) thio-1-propen-1- - silt C-cephem-4-carboxylic acid (compound 21, BB5-1091).
dissolved in 1 ml of water and poured onto a column with 100 ml of HP-20 phase. The column is washed with 500 ml of water and eluted with 30% methanol and then with 50% methanol. The fractions containing the desired compound were collected, evaporated, and lyophilized to obtain 170 mg (33%) of the desired product, the HPLC purity was 50%, m.p. (with different).
IR spectrum at KBG, „„, 3360, 3280, 1755, 1670.
UV spectrum in phosphate buffer, if / Houc (e): 235 (14,100); 252 (12300)
NMR spectrum in + DCl, chemical shift, MD: about 3.4 (4H, m,,); 5.43 (W, d, 4.5 Hz, 6-H); 5.15 (W, s, -CH-NDjj); about 6.0 (2H, m, 7-H and CH-CH -); 6.7 and 7.15 (each 2H, each d, HO-Ph-); 8.05 (1H, s, triazole-4-H).
Example 22. (Tert-butoxycarboxy-1-amino) -2-phenycetamido-3- (triphenylphosphonio) methyl-3-cephem-4-carboxylic acid benzhydryl ester, iodide (compound 22).
A mixture of 14.5 g (0,0196 mmol) of (-) - a- (tert-butoxycarbonylamino) a-phenylacetate-amido-3-iodomethyl-3-cephem-4-carboxylic acid benzhydryl ester of (-) a-4-carboxylic acid and 5 , 24 g (0.02 mol) of triphenylphosphine in 300 ml of ethyl acetate is stirred at room temperature for 2 hours. 200 MP ether is added to this reaction mixture to form a precipitate, which is collected by filtration and washed with ether, giving 14.3 g ( 73% of the indicated compound. The filtrate is concentrated to 50 ml and the concentrate is diluted with ether, yielding 2.4 g of an additional product yield. Total yield: 16.7 g (85%).
IR spectrum, KBG, -, 1780, 1690, 1480, 1420, 1350, 1240, 1150.
Example 23. Benehydride ester of (tert-butoxycarboxy-1-amino) -2-phenylacetamido-3- (Z) -l-propen-1-yl-3-cephem-4-carboxylic acid (compound 23).
To a solution of 5 g (5 mmol) of compound 22 in 200 MP of chloroform was added a mixture of 100 ml of water and 5 ml (5 mmol) of H, ijacTBOpa of caustic soda, and the mixture was shaken for 3 minutes. The organic layer is separated, washed with water and a saturated solution of NaCl and dried over anhydrous magnesium sulphate. The chloroform solution is filtered, the filtrate is concentrated to 100 mp under reduced pressure. To the concentrate was added 3 ml of acetaldehyde, the mixture was stirred at room temperature for 1.5 hours and evaporated to dryness. The oily residue is chromatographed on a column of 50 g of silica gel (silica gel 60), eluting with chloroform. The desired fractions are collected and evaporated to dryness, and the residue is triturated with n-hexane, -polucha 990 mg (31%) of the title compound 23
IR spectrum, KBG, dd cc 17: iO, 1710, 1660, 1510, 1490, 1360, 1240, 1210, 1150.
NMR spectrum, in CDClI, chemical shift, ppm: 1.3-1.5 (12H, m.C-CHj-); 322 (2H, s, 2-H); 4.93 (1H, d, 4.5 Hz, 6-H); 5.23 (1H, d, 8 Hz, CH-CO); 5.5 - 6.2 (3N, m, 7-H and vinyl-n); 6.94 (W, s, CHPh); 7.2-7.5 (15H, m, phenyl-H).
Example 24. Sodium α-amino-2-phenylacetamido-3- (Z) -l-propenyl-3-cephem-4-carboxylate (compound 24, BBS-1065).
A mixture of 0.94 g (1.47 mmol) of compound 23 and 3 MP of trifluoroacetic acid was stirred for 30 minutes at room temperature, then diluted with 50 ml of a mixture of ethyl ether and isopropyl ether (1: 1) to obtain about 800 mg of a precipitate. which is collected by filtration and dissolved in 3 ml of methanol. To the solution was added 4.5 ml (4.5 mmol) of a 10 solution of sodium 2-ethyl hexanoate in ethyl acetate, the mixture was diluted with 50 mp ether and then 50 ml of isopropyl ether. The precipitate is collected by filtration and 710 mg of crude product 24 is obtained, which is dissolved in 20 ml of water, and chromatographed on a column using 50 ml of a Rahr PAK-500 / C, j packer phase (Waters replaceable cartridge). The column was eluted with water and 10% methanol. The fractions containing the desired product are collected by analysis by the HPLC method, concentrated to 3 ml and lyophilized to obtain 182 mg (31%) of the desired product, melting at 200 ° C. Estimate purity by HPLC-50%.
IR spectrum, KBG, COP 1760, 1660, 1400, 1180, 1100.
UV spectrum in phosphate buffer (pH 7), -, nm (e): 282 (5500).
NMR spectrum in ppm: 1.60 (3N, d, 6 Hz, C-CH3); 3.12 (1H, d, 18 Hz, 2-H); 3.48 (1H, d, 18 Hz, 2-H); 5.03 (1H, d, 4.5 Hz, 6-H); 5.62 (W, d, 4.5 Hz, 7-H); 5.93 (1H, d, 10 Hz,
17 1407АОО. 18
vinyl H); 5.2-5.8 (IH, m, vinyl-H); lyophilized to obtain 60 mg of solid 7.41 (5H, s, phenyl-H) t product, melting at 200 ° C (noil p and me 25. Benzhydryl steppe. Rael.).
ether (tert-butoxycarbonyl-IR spectrum, KBG, ddax 1760,
amino) -2-phenylacetamido -3-tg) -3-® 1660, 1630, 1360, 1120, 1070.
chlor-1-propen-1-yl-3-cephem-4-car-UV spectrum in phosphate buffer,
side acid (compound 25). I;, а „, nm (e): 243 (12700), 200 puls to a solution of 2 g (2 mmol) of comi-cho (4200).
Example 22 (-) - 2-Ami50 ml of water containing 2 ml (2 mmol) but-2-phenylacetamido-3- (g) -1-propenG sodium hydroxide solution, a mixture -1-yl-3-cephem-4-carboxylic acid
Shake for 3 minutes. The organic layer (compound 24, BB-1065, in the form of amphiotdel and washed with water, then in-it).
with a solution of NaCl. Dried 15 g, Compound 23, dimethyl methyl chloroform solution is concentrated (tert-butoxy under reduced pressure to carbonate 1 amino) -2-Fench 1 acetamido -330 MP. To the concentrate was added 2 ml- (1-propenyl) -3-cephem-4-carboxylic
Chloracetadehyde. The mixture is stirred acid (2.34 mmol) is treated
at room temperature for 1 h, washing with 2o - ml of trifluoroacetic acid, mixture
wate with water and saturated solution is stirred for 20 minutes at room temperature.
NaCl. The organic solution is dried at a temperature and diluted with 100 ml of these is evaporated to dryness. An oily ether of ether, obtaining 1.15 g (96%)
Chromatograph the chromatography on a column of crude trifluoroacetate BBS-1065.
silica gel (50 g Bako-gel 0-200), 25 IR spectrum, KVg, μs 1760,
eluting with chloroform. Target. Fractions 1670, 1200, FROM.
collected and dryed to obtain a UV spectrum in phosphate buffer
534 g of crude product. (pH 7),, 283 nm ().
IR spectrum, KBG, y, and, 1780,1,1; G trifluoroacetate (2.25 mmol)
1710, 1660, 1500, 1490, 1360, 1240, DL are dissolved in 20 ml of water and the solution
1210, 1150. chromatograph on a column containing the structure of this sample is not supporting 100 ml of the gasket obtained from;
confirmed by the vagueness of its NMR-rger PAK-500 / C (replaceable cartridge of the corporate spectrum. - we are Waters). Column elute with water.
Example 26. Sodium 7 - in-2-. 10% methanol and 30% methano | -amino-2-phenylacetamido-3- (Z) -3-scrap, Eluate. 30% methanol concentration of chlorine-1-propene-1-sh11 (-3- Cephem-4-carburet up to 10 ml. Crystalline
Oxylate (Compound 26, BBS-1066). The product is isolated, collected and washed. The mixture 472 mg (0.7 mmol) is combined with acetone and dried under vacuum.
: Nor 25 and 1.5 ml of trifluoroacetic acid-40 with phosphorus dioxide. Get
1 lots are stirred for 15 min at 10-15 C. 505 mg (46%). Pure BBS-1065 (in a V | I diluted with 30 ml of a mixture of ether and isof de amphion), melting at 180; propyl ether (1g1) to semi-183 ° C (with decomp.). Evaluation of purity 330 mg of light yellow precipitate, 95%.
which is collected by means of a filter - g IR spectrum, KBG,) m "6s
of To a solution of the precipitate in 3 ml of methano- 1750, 1690, 1590, 1400, 1350.
2 ml (2 mmol) 2-ethyl-UV spectrum in phosphate buffer
sodium hexanoate in ethyl acetate and (pH 7), 3.0, 282 nm ().
The mixture is diluted with 50 ml of ethyl acetate. NMR spectrum in + NaKCO, chem.
The precipitate is collected by the gQ shift, ppm: 1:53 (MN, d, J 6 Hz,
filtration and washed with ether, semi-C-CH); 3.3 (2H, d, 2-H); 5.03 (W,
cha 244 mg of crude product (d, J 4.5 Hz, 6-H); 5.2 (1H, s,
solution of crude product in 10 ml of CH-CO); 5.1-5.8 (1H, m) J
water chromatographic on a column, EA-5.63 (W, d, J 4.5 Hz, 7-H); 5.92
Full 50 ml of the rger PAK-500 / C, jgg phase (W, d, J 12 Hz,); 7.4 (5H,
(replacement cartridge from the firm of Waters) .1Solon-s, phenyl-H),
(s is eluted with water and 10% methanol. Example 28. In (-) - 2- (trw-b. Target fractions in 10% methanol toxcarbonylamino) -2- (3-chloro-4-hydroxy) are combined and concentrated to 5 ml of ifenyl) acetic acid (compound 28).,
. (
. (
A mixture of 6 g (0.03 mol) of 3-chloro-4-oxiphenylglycine and 9.8 g (0.045 mol) of di-tert-butyl dicarbonate in 120 ml of 50% aqueous tetrahydrofuran containing 10 ml (071 mol ) triethylamine, stirred at room temperature for 3 hours. The mixture is concentrated to 60 ml and the concentrate is washed with ether. The aqueous layer is acidified with 6Nsol-10 precipitate, which is collected by
acidic acid and extracted with 200 mp ether. The extract is washed with water and a saturated solution of NaCl, dried over magnesium sulphate and aged to dryness to give 10 g of an oily residue, which does not solidify upon rectification and dried, to give 9.2 g of iodine phosphonium 30,
IR spectrum, KBG, „.tc, 1780, 1680, 1490, 1350, 1240, 1150.
15 Example 31. (Tert-Butoxycarbonyl-amino) -2- (3-chloro-4-hydroxyphenyl) acetam- (g) -1-propen-1-yl-3-cephem-4-carboxylic acid benzhydryl ether (compound 31)
15 Example 31. (Tert-Butoxycarbonyl-amino) -2- (3-chloro-4-hydroxyphenyl) acetam- (g) -1-propen-1-yl-3-cephem-4-carboxylic acid benzhydryl ether (compound 31)
A solution of 9.5 g (9 mmol) of compound 30 in 200 MP of chloroform is placed in a layer with a mixture of 100 ml of water and 10 ml of 1N sodium hydroxide solution, the mixture is shaken for 3 minutes. Organic layer
25 washed with water and saturated NaCl solution, dried over magnesium sulfate and concentrated to about 50% of the volume. To the concentrate was added 20 ml of 90% acetaldehyde, the mixture was stirred
extracted with 200 ml of ethyl acetate, the extract is washed with an aqueous solution
bleed ether with hexane.
Example 29. Benzhydryl ether) -2- (tert-butoxycarbonyl-amino) -2- (3-chloro-4-hydroxyphenyl) acetates 20 to 1-3-chloromethyl-3-cephem-4-carboxylic acid (compound 29),
To a solution of 6.2 g (0.015 mol) co. Units 2 and 5.4 g (0.018 mol) of compound 28 In 150 ml of dry tetrahydrofuran, 3.7 g (0.018 mol) of dicyclopoxylcarbodiimide are added, the mixture is stirred at room temperature for 1 hour. Dicyclohexylurea, which is released while stirring, is 30 at room temperature for removal by filtration and for 3 hours, treated with anhydrous sulfate; the filtrate is evaporated to dryness. The remainder is magnesium and filtered. The filtrate is evaporated to dryness, the residue is chromatographed on 120 g of kisel-gel (sodium bicarbonate, water and saturated Merck), eluting with a mixture of toluene and ethyl NaCl solution and dried over sulphate (4: 1). magni. The filtrate is evaporated and evaporated to dryness, the residue is dry, the oily residue is chromatographed with a mixture of ethyl and isopulated on a column with 140 g of silica gel, propyl ether and n-hexane, P-(Waco-gel C-200), 1.33 g of blocked product and ethyl acetate (10: 1) are eluted with a mixture of to-40. Target Ta 31.
IR spectrum, KBG, OIKU 1770, 1700, 1660, 1480, 1350, 1210, 1120. Example 32. 7 - B-2-Amino-45 -2- (3-chloro-4-hydroxyphenyl) acetamido -3- - (Z) -1-propen-1-yl-Z-cephem-4-carboxylic acid (compound 32, VMU-28060),
CttecJ} 1.33 g (1.93 mmol) of the compounds of 31 and 3 MP of trifluoroacetic acid are stirred at room temperature for 30 minutes, the mixture is diluted with 50 ml of 1: 1 mixture of ethyl and isopropyl ether to obtain 1.072 g of the crude mixture is stirred for 30 minutes at room temperature of 55 trifluoroacetate 32, which is at a chromate temperature. The mixture is concentrated on a column filled with a phase to 30 ml, to the concentrate is added Zoi rug PAK-500 / C (replaceable cartridge with 200 ml of ethyl acetate, the mixture is washed by Waters) (80 ml). The column was washed with water and 10% methanol with an eluent solution of Na S Oj, water,
the fractions are collected and evaporated to dryness to give 10 g of product 29,
IR spectrum, KVG,, 1720, 1680, 1500, 1370, 12ОО, 1160,
Example 30, Benzhydryl ester) -2- (tert-butoxycarbonyl-amino) -2- (3-chloro-4-hydroxyphenyl) acetamido-to-3- (triphenylphosphonio) -methyl-3-cep-4-carboxylic acid (compound - 1+ 30), iodide,
To a solution of 10 g (14.3 mmol) of compound 29 in 100 ml of acetone was added 11.2 g (75 mmol) of sodium iodide.
With an NaCl solution and dried over MgSO4. The ethyl acetate solution is filtered, the filtrate is concentrated to half the volume. 3.9 g (15 mmol) of triphenylphosphine was added to the concentrate, and the mixture was stirred for 2 hours at room temperature. 300 ml of ether is added to the solution to precipitate
filter and dry to give 9.2 g of iodine phosphonium 30,
IR spectrum, KBG, „.tc, 1780 ,. 1680, 1490, 1350, 1240, 1150.
Example 31 Benzhydryl ester of (t-butoxycarbonyl-amino) -2- (3-chloro-4-hydroxyphenyl) acetam- (g) -1-propen-1-yl-3-cephem-4-carboxylic acid (compound 31 ),
A solution of 9.5 g (9 mmol) of compound 30 in 200 MP of chloroform is placed in a layer with a mixture of 100 ml of water and 10 ml of 1N sodium hydroxide solution, the mixture is shaken for 3 minutes. Organic layer
washed with water and saturated NaCl solution, dried over magnesium sulfate and concentrated to about 50% by volume. To the concentrate was added 20 ml of 90% acetaldehyde, the mixture was stirred
at room temperature for 3 hours, treated with anhydrous magnesium sulphate and filtered. The filtrate is evaporated to dryness, the residue is chromatographed on 120 g of kiesel gel (Merck), the mixture is eluted with toluene and ethyl acetate (4: 1), the target fractions are collected and evaporated to dryness, the residue is triturated with a mixture of ethyl and isopropyl ethers and n-hexane, 1.33 g of blocked product is obtained 31.
 21140740022.
| 0% methanol is concentrated to a mixture of its 3- (and-4) mono-0-butoxy | 02 from the initial volume of the carbonyl derivatives (compound
iroM is isolated crystalline wasp-346).
A dock that is collected by g. A mixture of 8 g (19.3 mmol) of compound
filtration, washed with acetone and su-2.8 g of the mixed product of experience 33 and
 in vacuum over PjOj. 4.12 (20 mmol) of dicyclohexipcarbodii38 mg of compound 32 (purity 95%), imide in 200 ml of dry tetrahydrofuranol is obtained at 180–185 ° C (progressively stirred for 1 h at room temperature
Rael,). The filtrate is concentrated to temperature. The reaction mixture is precipitated in ml and liofed, 154 are stirred to dryness. The residue is dissolved in
additional product yield, 200 ml of ethyl acetate, insoluble
80% purity. (by HPLC). Material (dicyclohexylurea)
The IR spectrum, KBG, 1760, is removed by filtration. Filters & 80, 1570, 1410, 1390, 1350, 1290, 15rat are washed with an aqueous pactaopoM bicar1270, sodium bonate, water and a saturated UVF, phosphate buffer (pH 7), dried with sodium chloride,
nKotc (e): 232 VET, 280 with magnesium sulfate and evaporated to dryness
(10,500) under reduced pressure. Oily
NMR spectrum in DjO "NaHCO, chem. 20 residue chromatographic on a column
s, 5vig, ppm: 1.68 (ZN, d, J 6 Hz, with silica gel (130 g of gel-gel 60),
С С-СНз); 3.25 (w, d, J 18 Hz, eluting with toluene-ethyl acetate
2-H); 3.57 (W, d, J 18 Hz, 2-H); (5: 1). and then with the same mixture (2: 1),
 (1H, s, SNCO); 5.18. (1H, d, J Eluate with a toluene / ethyl ratio | 4, 5 Hz, 6-H); 5.72 (1H, d, J 25 acetate (5: 1) are collected and evaporated
| 4.5 Hz, 7-H); 5.5-5.9 (1K, m, dry, to obtain g mono-0C mixture); 5.97 (W, d, J 12 Hz,); .- tert-butyloxycarbonyl (BOC) -N-BOC
7.02 (1H, d, J 8 Hz, phenyl-H) I-protected derivatives 346. Eluate
7.3 (JH, d, jJ 8 and 1.5 Hz, phenyl-N); with a toluene / ethyl acetate ratio of 7.50 (1H, d, 1.5 Hz, phenyl-H). 302: 1 Collect and dry.
Example 33. C (-) - 2- (tert-bu-3 g 3 4-dioxyphenyl
t (xicarbonstamine) -2- (3,4-dioxyphe-derived 34a.
) acetic acid (compound ZSa) Compound 34d: IR spectrum, KBG,
mixed with its 3- (and-4) - mono-O-butox -. , 1720, 1690, 1500,
Kc of the carbonyl derivatives (compound, 1240, 11507. Hi | e ЗЗб). NMR spectrum in CDCl, chem. shift..
A mixture of 3.66 g (20 mmol) of 3,4-diox-ppm: 1.42 (9H, s, C-CH,); 3.4 (2H,
C1: phenylglycine and 9.24 g (40 mmol) -pgar, s, 2-H); 4.30 (2H, yy pp,
di-tert-butyl dicarbonate in 120 ml of 50% -.); 4.85 (1H, d, J 4.5 Hz,
Hcjro of an aqueous solution of tetrahydrofur-406-H) j 5.07 (1H, d, J 6 Hz, CH-;
n4 containing 10 ml (71 mmol) tri-NH); 5.74 (LH, dd, J 9 and 4.5 Hz,
E7) ilamine, stirred for 16 h at com-7-H); 6.6-6.9 (3N, m, f-enyl-N); 6.93
at a high temperature and a mixture of concentrated (1H, s, CHPp) ;; 7.3 (10H, s, phenyl-H). Draw up to 60 ml. The concentrate is washed; Mix 34b. IR spectrum, KBG ,,,,
10 | 0 MP ether, acidified with 1N salt 45cm: 1770, 1720, 1690.1500, 1370,
Slot and extract with ether 1240, 1150.
(ibOx2 ml). Combined extracts NMR spectrum in CDCl, chem. shift,
Rinse with water and lactation (diluted ppm: 1.42 (9H., C — CHj); 1.55 (9H, s,
roC NaCl, dried with magnesium sulfate C — CH j); 3.4 (2H, brs, 2-H); 4.35
and dry to give 8 g of ma- 50 (2H, br.s, CHgCl); 6.9-7.1 (4H, m
sline residue, which is represented by-CHPh and phenyl-H); 7.3 (YUN, phenyl-N), l 1at is a mixture of the target derivative Example 35. Benzhydryl
3,14-dioxyphenyl and 3- and 4-mono-O-bu-ester of (-) - 2- (tert-butoxycarboto sicarbonylprotected derivatives of nylamino) -2- (3,4-dioxyphenyl) acetates Example 34, Benzhydryl 55 to 3- Triphenylphosphoniomethyl-3-cefemefir (-) - 2- (tert-butoxycarbo - 4-carboxylic acid, iodide (35a). niamino) -2- (3,4-dioxyphenyl) acetamide- 3 g mixture (4.4 mmol) product
to 1-3-chloromethyl-3-chloromethyl-3-cephem-34a and 3.3 g (22 mmol) of sodium iodide
-4 lcarboxylic acid (compound 34a) in 50 ml of Acetone is stirred at
room temperature 30 minutes, dare concentrated dry. The residue is extracted with ethyl acetate (100 ml), the extract is washed with an aqueous solution, water and a saturated NaCl solution. After drying over magnesium sulfate, the extract is concentrated to 60 MP. 1.4 g (5.3 mmol) of triphenylphosphine was added to the concentrate, and the mixture was stirred for 1 hour at room temperature. 100 ml of ether are added to the mixture to precipitate out which is collected by filtration - and washed with ether to obtain 3.2 g (70%) of phosphonium iodide (35a),
IR spectrum, KVG,
 . cm 1780, 1680, 1480, 1430, 1360, 1240, 1150.
In a similar procedure, 9.5 g (12 mmol) of a mixture of mono-0-BOC-protected derivatives (346) is reacted with sodium iodide and then with triphenylphosphine to obtain 10.7 g (77%) of a mixture of the corresponding derivatives of mono-O -BOCK-K-BOC-trifenonylphosphoniometryp (356),
1770, 1240,
IR spectrum, KVG,)
glax
cm1720, 1680, 1480, 1430, 1360, 1140.,.
Example 36 Benzhydryl ether (-) - 2- (tert-butoxycarbonylamino) -2- (3,4-diokeiphenyl) acetam- (2) -1-propen-1-yl} -3-cephem-4-carboxylic acids (Zba compound).
To a stirred solution of 3.15 g (3 mmol) of compound 35a and 10 ml of acetaldehyde in 50 mp of chloroform was added dropwise 8 mp (4 mmol) of 0.5N sodium hydroxide solution over 10 minutes, the mixture was stirred for 1 hour at room temperature. The reaction mixture is washed with water and a saturated NaCl solution, dried over magnesium sulfate and evaporated under reduced pressure. The oily residue was chromatographed on a column of 60 g of silica gel (Waco-gel C-200), which eluted with 2 l of chloroform and 2% methanol in chloroform, and analyzed by TLC (chloroform-methanol 10: 1). The target fractions from the 2% methanol eluate are collected and evaporated to dryness, yielding 0.8 g (40%) of the propenyl Zba derivative.
NMR spectrum in CDClj, chemical shift, MJ: 1.28 (3N, d, J 6 Hz, C — CHj); 1.42 (9H, s, C-CHj); 3.25 (2H, s, 2-H); 4.92 (1H, d, J - 4.5 Hz, 6-H); 5.08 (1H, d, J 6 Hz,, CH-H); 5.3 5, 8 (1H, m,); 5.80 (IH, d, J 4.5 Hz, 7-H); 6.04 (1H, d, J 11 Hz,); 6/70 (2H, s, phenyl-H); 6.82 (1H, s, phenyl-H); 6.92 (1H, s,
CHPh); 7.3 (YUN, s, phenyl-N).
In a similar manner, 10.5 g (9.3 mmol) of a mixture of 3- and 4-0-BOK-N-BOK-disprotected derivatives 356 with acetaldehyde is reacted with acetaldehyde, yielding 3.3 g (46%) of the corresponding 3-pr penile derivative 366.
IR spectrum, KVG, (ax,
5 1700, 1500, 1370, 1240, 1150.
NIR spectrum, chem. shift in CDCl1, MD: 1.4 (9H, s, C-CH); 1.55 (9H, s, C-CH, j); 3.25 (2H, s, 2-H); 6.07 (1H, d, J 11 Hz,); 6.9-7.1
0 (4H, m, CH-phenyl and phenyl-H); 7.3-7.5 (UN, m, phenyl-N).
Example 37.) -2-Amino-2- (3,4-dioxyphenyl) acetamido-3- - (g) -1-propen-1-yl-3-cephem-4-carboxylic acid (compound 37, VMU-28068). .
A mixture of 0.8 g (1.2 mmol) of Zba compound, 0.8 MP of anisole and 3 ml of trifluoroacetic acid is stirred.
0 5 min at room temperature and diluted with 25 ml of ether (diethyl) and 25 MD of isopropyl ether. The precipitate is collected by filtration and washed with isopropyl
g with ether, to obtain 557 mg of crude trifluoroacetate salt of compound 37. The solution of the crude product in 10. ml of water is purified by chromatography on a column filled with
0 100 ml of the PAHR-500 / C rger phase (replaceable cartridge from Waters), elute with water and then 5% methanol. The methanol eluate (5%) containing the desired product is concentrated to
5 volumes of 5 ml and lyophilized to obtain 231 mg (47%) of compound 37 (as an amphion, purity 90%). T. pl. 200 ° C (gradual decomp.).
IR Spectrum, Ake ™ 1760,
0 1690, 1580, 1530, 1400, 1360, 1290, 1270.
UV spectrum, phosphate buffer (pH 7),
 make
km (e): 233 (9200), 281
five
(1I000).
NMR spectrum, him. shift in md: 1.68 (3N, d, J 6 Hz, C-Ch 3.26 (1H, d, J 18 Hz, 2-H); 3.58 (1H, d, J 18 Hz, 2-H); 5.18 (W, s, CHNH); 5.22 (1H, d, J 4.5 Hz,
3) J
25
6-H); 5.5-5.9 (2H, m, and 7-H); 5.97 (1H, d, J II Hz,); 7.05 (3N, m, phenyl-N),
Similarly, from 3.3 g (4.3 mmol) M, 0-di-tert-BOC-purified derivatives of mixture 366, 1.3 g (75% 7 of compound 37 in the form of amphion (90% purity), which has spectra, identical to the above.
Example 38. In (-) - 2- (tert-β-Loxycar6-nonyl-amino) -2- (A-hydroxy-3-methoxyphenyl) acetic acid (compound 38),
A mixture of 2.96 g (15 mmol) of D (-) - 2- -amino-2- (4-hydroxy-3-methoxyphenyl) acetic acid and 3.6 g (0.0655 mol) of di-tert-butyl dicarbonate in 100 A ml of 50% aqueous tetrahydrofuran containing 4.2 ml (0.03 mol) of triethylamine is stirred for 16 hours at room temperature, the reaction mixture is concentrated to 50 ml. The concentrate is washed with 50 ml of ether, acidified with 1N hydrochloric acid and extracted twice with ether (100 ml). The combined extracts are washed with water and the above sodium chloride solution. The dried extracts are dried to obtain 4.38 g of compound 38 as a solid foam,
NMR spectrum, him. shift in CDCl, j, A. 1.4 (9H, s, -C-CH3); 3.8 (ЗН, s, OCHj); 5.15 (1H, d, J 6 Hz,: Н – Ш); 6.85 (3N, p, phenyl-N) .. j Example 39. Benzhydryl ether (-) - 2- (TpeT-6yTOKCHKap6o-lilamino) -2 - (4-hydroxy-3-methoxyphenyl) -acetamido-3- chloromethyl-3-cephem-4-carboxylic acid (compound 39),
A mixture of 4.3 g of compound 38.5 g (12 mmol) of compound 2 and 3 g (15 mmol) of dicyclohexylcarbodiimide ft 150 ml of dry tetrahydrofuran is sieved and evaporated to dryness to give 7 g of 3-chloromethyl cephemum, compound 39, as a solid foam, NMR -spectrum, chemical, shift, ppm: 1.4
(9H, s, C-CHj); 3.45 (21, br., S, 2-H); 3,83. (ZN, s, OCH,); 4.32 (2H, s, -CH, g, C1); 4.92 (W, d, J 4.5 Hz, 6-H); 5.13 (1H, d, J b Hz, CHNH);
10 5.65 (1H, d, J 6 Hz, NH); 5.80 (1H, dd, J8 and 4.5 Hz, 7-H); 6.85 (3N, phenyl-H); 6.95 (1H,: C, CH-Ph); 7.2-7.5 (UN, m, phenyl-N).
Example 40, Benzhydryl
15 ester of (-) - 2- (tert-butoxycarbonylamino) -2- (4-hydroxy-3-methoxyphenyl) acetamido-3-triphenylphosphonio-methyl-3-cepheme-4-carboxylic acid, iodyl (compound 40),
20 A mixture of 7 g (10 mmol) of compound 39 and 7.5 g (50 mmol) of sodium iodide in 100 ml of acetone is stirred at room temperature for 30 minutes and evaporated to dryness. Solution
2S of the residue in 200 ppm of ethyl acetate is washed in an aqueous solution, with water and an NaCl solution, dried with magnesium sulfate and concentrated to 100 MP, 3.1 g are added to the concentrate.
30 (12 mmol) triphenylphosphine, the mixture is stirred for 1 hour at room temperature, 100 ml of ether are added to the reaction mixture and the precipitate is collected by filtration, washed with ether and dried to obtain 5.8 g of triphenylphosphonium derivative of compound 40, the ether filtrate is concentrated to 10 ml, 300 MP ether is added to the concentrate to get
40 0.9 g of product as an additional yield. Total yield 6.7 g.
Example 41. (-) - 2- (tert-butoxycarbonylamino) -2- (4-hydroxy-3-methoxyphenyl | benzhydryl ether) is mixed for 2 hours at room temperature — acetamido-3- (2) -1-pro- -l - 3-cephem-4-carboxylic acid (compound 41),
To a stirred mixture of 5.8 g (5.5 mmol) of compound 40 and 10 mp 50 of 90% acetaldehyde in 100 ml of chloroform are added dropwise 11 ml (5.5 mmol) of 0.5 g of sodium hydroxide solution over 25 minutes, the mixture is stirred for 2 hours at room temperature. The precipitated urea is removed by filtration, the filtrate is evaporated to dryness. A solution of the residue in 200 ml of ethyl L-acetate is washed with an aqueous solution (sodium bicarbonate, water and saturated NaCl solution, dried with aa nng sulfate and evaporated to dryness. The oily residue is chromatographed on a column with 100 g of silica gel (
 60), which is eluted with a mixture of togg perurature. The reaction mixture was washed with luola and ethyl acetate (4; 1), analyzed with water, then with a saturated solution of Zlyuta by TLC (developed with tolu- NaCl, dried with magnesium sulfate and with 1: 1 ol / ethyl acetate or chloroform / dry . The oily residue tanol 50: 1) .- The target fractions are collected by chromatography on a 130 g column.

40740026 ..
are evaporated to dryness to obtain 7 g of 3-chloromethyl cefem, compound 39, as a solid foam, NMR spectrum, chemical, shift, ppm: 1.4
(9H, s, C-CHj); 3.45 (21, br., S, 2-H); 3,83. (ZN, s, OCH,); 4.32 (2H, s, -CH, g, C1); 4.92 (W, d, J 4.5 Hz, 6-H); 5.13 (1H, d, J b Hz, CHNH);
10 5.65 (1H, d, J 6 Hz, NH); 5.80 (1H, dd, J8 and 4.5 Hz, 7-H); 6.85 (3N, phenyl-H); 6.95 (1H,: C, CH-Ph); 7.2-7.5 (UN, m, phenyl-N).
Example 40, Benzhydryl
15 ester of (-) - 2- (tert-butoxycarbonylamino) -2- (4-hydroxy-3-methoxyphenyl) acetamido-3-triphenylphosphonio-methyl-3-cephem-4-carboxylic acid, iodyl (compound 40),
20 A mixture of 7 g (10 mmol) of compound 39 and 7.5 g (50 mmol) of sodium iodide in 100 ml of acetone is stirred at room temperature for 30 minutes and evaporated to dryness. Solution
2S of the residue in 200 ppm of ethyl acetate is washed in an aqueous solution, with water and an NaCl solution, dried with magnesium sulfate and concentrated to 100 MP, 3.1 g are added to the concentrate.
30 (12 mmol) triphenylphosphine, the mixture is stirred for 1 hour at room temperature, 100 ml of ether are added to the reaction mixture and the precipitate is collected by filtration, washed with ether and dried to obtain 5.8 g of triphenylphosphonium derivative of compound 40, the ether filtrate is concentrated to 10 ml, 300 MP ether is added to the concentrate to get
40 0.9 g of product as an additional yield. Total yield 6.7 g.
Example 41 Benzhydryl ester of (-) - 2- (tert-butoxycarbonylamino) -2- (4-hydroxy-3-methoxyphenyl2714074
silica gel (Kieel gel 60), eluting it with a mixture of toluene and ethyl acetate (the ratio gradually changed to 4: 1 (1.3 l), 3: 1 (1.1 l), 2: 1 (1.0 l) and the eluate collected in fractions of 20 ml each; Fractions 26 to 59 are combined and evaporated to dryness to give 830 mg of the desired 3-propenyl derivative of compound 41 as a solid foam.

Q
NMR spectrum in CDClj, chemical, shift, m, d,: 1.35 (3N, d,); 1.4 (9H, s, C-CHj); 3.85 (ЗН, s, O-CHj); 6.07 (1H, d, J 11 Hz, -CH-C).
Example 42, (-) - 2-Amino-2- (4-ox cy-3-labels, syphenyl) acetamido-to-3- (g) -1-propen-1-yl-3-cephem-4- -carboxylic acid (compound 42, VMU-28097),
A mixture of 830 mg (1.2 mmol) of compound 41, 0.5 MP anisole and 2 ml of trifluoroacetic acid is stirred at room temperature for 5 minutes, the mixture is diluted with 30 ml of ether (ethyl) and 30 ml of isopropyl ether. The resulting precipitate is collected by filtration, washed with isopropyl ether and dried, yielding
the course of the experiment gave water. Volume ml ml collected at different time intervals:
0-2 h 2-4 h 4-6 h 6-24 h Su
15 18 19.5 13 42 92
The urine (about 90 ml) is acidified to pH 3 with 1 normal hydrochloric acid and filtered to remove the precipitate. The filtrate is chromatographed.
20 on a column filled with 300 ml of HP-20 phase; the column was eluted with 2 l in dyes and 2 l of 30% methanol, the analysis of the eluates by the method GHUR, fractions containing biologically active com
25 nentas are collected in a 30% methanol eluate, concentrated to 10 ml and lyophilized, giving 390 mg of a brown solid. A solution of this substance in 20 ml of chromate water.
437 g of crude trifluoroacetate are computed on a column filled with
unity 42, Neochischen w product hro. They are mapped on a plate filled with 100 ml of the PAK-500 / Cj rger phase, (Waters exchangeable column), which is eluted with water and 5% methanol. The eluate of 5% methanol is concentrated to 5 MP and lyophilized, the beam is 225 mg of the compound 42 (amphion, purity 90%), T, pl, 176-180 C (decomp.,).
35
The 200 MP phase of the PAHR-500 / S ,, rger (replaceable cartridge from Waters), successively was spiked with water, 5% methanol, and 10% methanol. The first 5% methanol eluate is centered to 5 ml and a crawl of 44 mg of compound 37 (pure 70%) containing impurities transferred from the urine is lyophilized. Second half 5%
The Q methanol eluate is concentrated to 5 ml and lyophilized to obtain 36 m of product, which is a mixture of compound 37, compound 42 of impurities transferred from urine. Elua
cm
1760,
IR Spectrum, 1690, 1590, 1530, 1400, 1360, 1280,
UV spectrum in phosphate buffer (pH 7), 71, nm (e): 235 (10,000), 280 (11,000),
NMR spectrum in, chemical, shift, m, d,: 1.68 (3N, a d, J .6 Hz, C-CHj); 3.25 (1H, d, J 18 Hz, .2-H); 3.57 (1H, d, J 18 Hz, 2-H); 4.01 (ЗН, s, OCHj); 5.10 (1H, s, CH-CO); 5.19 (JH, d, J 4.5 Hz, 6-H); 5.78 (1H, d, J 4.5 Hz, 7-H); 5.5-5.9 (1H, m, ...); 5.98 (1H, d, J 11 Hz,);
The Q of the methanol eluate is concentrated to 5 ml and lyophilized to obtain 36 mg of product, which is a mixture of compound 37, compound 42 and impurities transferred from urine. Eluate
D5 10% methanol (about 600 ml) was concentrated to 5 ml and lyophilized to give 38 mg of compound 42 (purity 70%, according to HPLC), which was rechromatographed on a column with the same gasket as above (40 ml) , elute with water, 5% methanol and 10% methanol. The target fractions eluted with 10% methanol are combined and concentrated to 5 nl and lyo50.
; 7.07 (2H, s, phenyl-H); 7.17 (1H, broad, 55 Filtered to obtain 16 mg of Compound C, phenyl-H) .42. with a purity of 90%, according to HPLC
 HPLC: retention time 9.3 min. (.0.02 M acetate buffer with pH 4 — ace- (0.02 M acetate buffer with pH 4, containing tonitrile 85:15). Mp. 180 ° C. ( Suffer 15% acetonitrile..step, decomp.,).
07400
28
EXAMPLE 43. The isolation of compound 42 from the urine of rats treated with compound 37,
Six Whistler female rats (weight 400-600 g) were placed in steel metabolic cells after oral administration of compound 37 at a dose of 100 mg / kg and the urine of rats was collected for 24 hours. The rats were fed regularly and in
the course of the experiment gave water. The volume of urine ml collected at different time intervals:
0-2 h 2-4 h 4-6 h 6-24 h Total
18 19.5 13 42 92.5
The urine (about 90 ml) is acidified to pH 3 with one-normal hydrochloric acid and filtered to remove the precipitate. The filtrate is subjected to chromatography on a column filled with 300 ml of HP-20 phase; the column was eluted with 2 l of water and 2 l of 30% methanol, analyzed by HPLC. The fractions containing the biologically active components in the 30% methanol eluate were collected, concentrated to 10 ml and ethofilized to obtain 390 mg of a brown solid. A solution of this substance in 20 ml of water chromate
The 200 MP phase of the pager PAK-500 / S ,, (replaceable cartridge of the company Waters), is successively deflated with water, 5% methanol and 10% methanol. The first half of the 5% methanol eluate is concentrated to 5 ml and lyophilized, crawling 44 mg of compound 37 (70% purity) containing impurities transferred from urine. Second half of 5%
the methanol eluate is concentrated to 5 ml and lyophilized to obtain 36 mg of product, which is a mixture of compound 37, compound 42 and impurities transferred from urine. Eluate
10% methanol (about 600 ml) is concentrated to 5 ml and lyophilized to give 38 mg of compound 42 (purity 70%, according to HPLC), which is re-chromatographed on a column with the same gasket as above (40 ml), Elute with water, 5% methanol and 10% methanol. The target fractions eluted with 10% methanol are combined and concentrated to 5 Nl and lyo
IR, KBr, cm: 1760, 1690, 1590, 1530, 1400, 1360, 12bO. UV spectrum (phosphate buffer pH 7), 1:, nm (e): 233 (8200), 280 (8800). g i NMR spectrum (DO), chem. shift, | ppm: 1.68 (3N, d, J 6 Hz, C-CH); | 3.26 (1H, d, „J 18 Hz, 2-H); 3.58 1 (1H, d, J 18 Hz, 2-H); 4.01 (3N, s, CHj) j 5.12 (W, s, CH-CO); 5.21 (W, d, J 4.5 Hz, 6-H)} 5.78 (1H,
ten
15
to penicillin. Gp-1b organisms are gram-positive staphylococci that are resistant to penicillin and produce penicillinase. Go-1a organisms are gram-negative bacteria that are sensitive to ampicillin and cefapotin. The compounds of the invention generally have a reduced activity against gram-negative bacteria resistant to ampicillin and cephalothin. From tab. 2, we can draw the following 15 conclusions regarding the antimicrobial activity of these compounds outside the body.
All compounds have good activity against staphylococci.
J 4.5 Hz, 7H); 5.5-5.9 (W, m,
); 5.98 (1H, d. J 11 Hz,); 7.07 (2H, s, phenyl-H); 7.17 W, br.s, phenyl-N),
The structure of the metabolism product is established as (-) - 2-amino-2- (4-hydroxy-3-methoxyphenyl) acetamido-3- (2) -1-lropen-1-yl-3-cephem-4-carZonic acid by means of - 20 sensitive to penicillin (Гп-1а). 1Ni NMR, IR, UV and chromium- spectra. Usually they are less active (in three or 1–2 g / h of HPLC with compound 42, more or less, times) against staphylococci isolated by the methods of examples resistant to penicillin (Hn-1b). One is J8-42-, in each case these compounds in
Pharmacological testing of compounds is 23 times more active than those that confirm their anti-myxhlexine and cefadroxil. 11 | 0by activity, are given in below. Satisfactory activity
against gram-negative bacteria (Go-1a), only those NIN compounds possessing an unsubstituted 4Hc (Z) -propenyl group in the -3 position. These are compounds 9, 24, 32, and 42. The trans- (E) -propenyl substance, compound 8, possesses eight times and li some compounds contain e-35 ™ activity against Gramus B of the table. 1 shows the structure of the products of examples 1-43. Most of these compounds are - (B-phenylglyceramido) cefaposporins 5 II of which there is a 1-propen-1-yl group in position 3, the terminal atom of the hydrogen of the propenyl substituent
A tester, such as an apical group (methyl), a halide (chlorine or iodine), a 4-acryl group (phenyl) heterocycly-1 thio group (1,2,3-triazol-5-Nyl-thio) or an alkoxy group (marks-c1-). The phenylglycylamido group can be unsubstituted, or mono- or / (isomeric of the hydroxy, alkoxy group or a halogen atom.,
In tab. Figure 2 shows the opposite; bacterial activity outside the body of the proposed compounds. The values of the minimum inhibitory concentration are given, which were determined by agar dilution method for three groups of organisms, designated Gp-1a, Gy-16 "Go-1a, Each of these three g |
telny bacteria compared with the corresponding cis-propenyl compound -9. Similarly. Substitution of the terminal methyl group in propenyl
The 40 substituent at position -3 appears to lead to a decrease in gram-negative activity. These are compounds 13, i5, 21 and 17. This is also true for vinyl compound 1I. However, these compounds are potential antimicrobial agents that are almost equivalent to cefalexin and i cefadroxil. The substitution in the ring is in no way deteriorated.
gQ sews antimicrobial activity. Compare compounds 9, 24, 32 and 42. It appears that compound 37 is an exception, but in fact it is a highly active compound
e) ividual microbial strains, gg against gram-positive and gram-negative bacteria, as shown in Table 3.
The phthroids are identified in a footnote to the. blue, 2, Gp-1a organisms are gram-positive staphylococci, which are sensitized
0
to penicillin. Gp-1b organisms are gram-positive staphylococci that are resistant to penicillin and produce penicillinase. Go-1a organisms are gram-negative bacteria that are sensitive to ampicillin and cefapotin. The compounds of the invention generally have a reduced activity against gram-negative bacteria resistant to ampicillin and cephalothin. From tab. 2, the following 5 conclusions can be drawn regarding the antimicrobial activity of these compounds outside the body.
All compounds have good activity against staphylococci.
Only those compounds in which there is an unsubstituted 4Hc (Z) -propenyl group in the -3 position have the opposite of gram-negative bacteria (Go-1a). These are compounds 9, 24, 32, and 42. The trans (E) propenyl substance, compound 8, has eight times ™ activity against gram-negative bacteria compared with the corresponding cis-propenyl compound -9. Similarly. Substitution of the terminal methyl group in the propenyl
substituent in position -3, apparently, leads to a decrease in gram-negative activity. These are compounds 13, i5, 21 and 17. This is also true for vinyl compound 1I. However, these compounds are potential antimicrobial agents that are almost equivalent to cephalexin and i cefadroxil. The substitution in the ring is in no way deteriorated.
antibacterial activity. Compare compounds 9, 24, 32 and 42. It appears that compound 37 is an exception, but in fact it is a highly active compound
against gram-positive and gram-negative bacteria, as shown in table 3,.
In tab. 3 contains comparative antimicrobial activity.
the stump of the body against the same organiza- tion as in table. 2, using two different microbiological culture media. Agar Mueller-Hinton is the standard medium used in the tests related to table. 2, in table. 3 contains a comparison of the minimum inhibitory concentrations for tr .. test compounds that were determined initially in Mueller-Hinton medium and then in nutrient agar dp of compound 9, which contains an A-hydroxy substituent in the phenyl ring and compound 42, which contains a 3-methoxy-4-hydroxy substituent in the phenyl ring, only moderate environmental effects are observed. This means that the differences in the minimum inhibitory concentrations do not exceed threefold. Compound 37, a 3,4-dioxyphenyl substituted compound, illustrates the difference in activity between two media, which is from 600 to 1200%, and the minimum inhibitory concentration in nutrient agar is much lower than in Noeller-Hinton agar. In line with this, the antimicrobial effect of compound 37 is comparable to that of other cephalosporins with a cis-propenyl group in position -3, which are listed in Table. 2
The correlations between structure and activity, derived from these studies outside the body, are confirmed by the results of in vivo studies in mice. In tab. 4 summarizes the protective doses for mice infected with a lethal bacterial seed culture (oral treatment). In this study, two different types of bacteria were used: gram-positive and gram-negative. The protective dose (SDS) is the dose that, when administered to a group of infected mice (5 individuals), leads to 50% survival after 5 days. (found by interpolating from dose response curve). Normally infected untreated mice die within 3 days after infection with a lethal inoculum.
The data in the table. 4 composed of several different experiments. Cefalexin was used as a control treatment in these experiments. The ZD value found for cefalexin in the same experiment is shown in parentheses immediately after the magnitude of the ED for the test compound. Obviously, ka-adnC from cephalosporins has good activity against Gram + Stap-
Q hylococcus aureus and that compounds with a cis-propenyl group at position -3 are more active against gram-negative infection — compounds 9, 24, 37.
5 In table. 5 contains comparative data on the content of the compounds in the blood of mice treated orally and intramuscularly with the test compounds indicated in Table. 1. Alone
Q into good oral absorption is observed for all compounds except for compound 21, which has a heterocyclic thio-substituent in the 3-propenyl group. For
5 of compound 37, an exceptionally high blood level of mice was observed after oral administration. It has been shown that this compound, when metabolized in rats, is converted to compound 42 (see Example 43). Compound 37 is a 3,4-dioxiphenyl compound, and Compound 42 is 3-. 1-methoxy-4-hydroxyphenyl compound. The latter compound has a high activity in the body (in vivo) and outside the body (in vitro). In tab. 6 contains additional in vivo data for compound 9 against four other organisms in
compared with cefapoxin, cefaclor and cefadroxnl. Tables 7 and 8 contain comparative in vitro data for compound 9 versus cefapexin, cefadroxyl and cepha-chloro for a range of streptococci, Neisseria, Haemophilis and various anaerobic bacteria.
In rat urine excretion, urinary excretion of compound 9 within 24 hours of oral rats was comparable to that of f for cefalexin and cefadroxil and higher than for cefachlor. A study of the stability of compound 9 compared with celexin and cefachlor in solution using phosphate buffer at pH 6.5 m, pH 7.0, human serum (pH 6.8), horse serum (pH 7.6), and calf serum
five
five
33140740034
(pH 6.8) as carriers show that compound 9 is substantially R2-v / -CHCONH more stable than cefachlor and compared in stability with cephalexin,
NHR Oh

权利要求:
Claims (1)
[1]
Invention Formula
CHgO COOR4
where R, R and R have the indicated meanings.
The method of producing substituted vinyl is reacted with triaryl cephalosporins of general formula Q with phosphine at room temperature.
in an environment of a water-immiscible organic solvent in the presence of an aqueous alkali, the resultant phosphorus compound
Rj- V CHCdNH-i-PG
   I - ..
RH of T-CH-CHRj
C.OOR.A15 is treated under anhydrous conditions.
at room temperature the carbonyl de r. - hydrogen or amino-protective compound of general formula
a group such as t; butoxycarbonyl; R CHO,
K - hydrogen, hydroxyl, halogen 20
or a lower alkoxy group; where R - has the indicated meanings,
followed, if necessary, by the removal of the amino-protecting group or ester group, and in the R4 hydrogen or hydroxyl group; RJ - C, -Sf-alkyl or C-C aralkil
R is hydrogen or ester 2§ of the desired product.
Group
a 2-configuration with respect to an ecocyclic double bond, such as; inhibition in general formula
21 (BBS-109I)
(He is -CH2- $ D JN
CHCONH I
NHR Oh
Priority signs: 28,01,83 - when R. - hydrogen or hydroxyl, R - hydroxyl;
28.12.83 when R is halogen or 30 lower alkoxy, Rg is hydrogen, Table 1
 The average for five organisms of each group: Гп-1а, gram-positive staphylococci: sensitive to penicillin; penicillium. not formed: S. aureus Smith A9537, S. aureus A9497, S. aureus Terajima, S. aureus A9534, S, .aureus A9601,
Gp-16 gram-positive staphylococci resistant to penicillin; penicillinase producers: S, aureus 193, S. aureus BX-1633-2 A9606, S. aureusVA15092, S. aureus Russell, A. aureus A9602;
Go-la gram-negative bacteria, sensitive to ampicillin and cephalothin: E. coli Jiihi. A15119, E, coli A9660, K, pneumonia flil, P. mirabilis A9554, P. mirabflis A9900. . He is part of testing D, a separate test.
 A: Noeller-Hinton agar. B: nutritional agar.
 Average values for the same groups of organisms as in table. 2
Values in parentheses are data for cefalexin
same experience
In this experiment, a dose of 0.16 mg / kg was obtained for BMP 28100; control values for cefalexin or defadroxyl are not available.
P
00
00
about evi
Gh
"N" N | - CM
- N n in
r o
CO io
Co so
ch o
oh oh oh
I I
00 CS
"P
(H
  t D f yQ rt
N n n CO - or- “M CM CM - CM 00
VO
N sf 2: 0 I ° o: 5 "22
 CO CO
 ,
CM - -,. tM
00
"
 -. f.
RON sf "00
IM - r
  . . - - - CM
CO o "st
n vO
VOvO r.
o00
53 and te
nn pq
mn m
-
sf CM
00 in
-
O
t fO CO
mm -
- enGCH
CM
ch o
about
- about
IT) vO
oh oh
o (o
sf co
0000
oo
00
- Sch
about -
year
with
s
VO
CO o - - f MF C "4
VO CO S rx.
- - “-
o
VOrx -
VO
about to -
fx
-
00
CM
"L
IT OV
o
: oo 00
lO "
- l r.
CO OFC
r. fl
CO VO I vO
about 00:
Iv. NO
CO vO VO
r
VO
r
". -
CO
CO
 r Yu
YU
-
sf
CO
r
rx
"
VO. CO1L) o-
in VO CO СЧ 00 in
I n
vO
r.
0
te
pq
m
n
5h Ov1
2 2§
II and
CO CO
mm01
mme
v
- GC
about - N
oin
with VO
s 00o
about CM-
to II
about 31 m
mm
em - ft
 F
PH; sf: “m
o00
VOVO
oo
00с CMcm
1I
CM r
CO CO
at
TO
about
I
&
n s
Sh
yo
five
ex
CJ
Organism
The minimum inhibitory concentration.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1407400A3|1988-06-30|Method of producing substituted vinylcephalosporins

---

US4201782A|1980-05-06|Thiadiazolyl cephalosporin analogs

---

US4217448A|1980-08-12|Antibacterial compounds

---

US4150156A|1979-04-17|7-|-3-|-cephalosporins, derivatives and pharmaceutical compositions containing them

---

FI60870C|1982-04-13|PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF O-SUBSTITUTES 7BETA-AMINO-3-CEFEM-3-OL-4-CARBONSYRAFOERENINGAR

---

US4207323A|1980-06-10|6-Substituted methyl penicillins, derivatives and analogues thereof

---

EP0049119B1|1986-01-15|Cephalosporin derivatives, a process for their preparation and compositions containing them

---

US4760060A|1988-07-26|3-heteroaralkylthio carbacephem compounds and antibacterial pharmaceutical composition

---

EP0236231B1|1994-05-04|Novel cephem compounds

---

SU1155159A3|1985-05-07|Method of obtaining cephalosporin derivatives or their salts with alkali metals

---

US4731362A|1988-03-15|Alkylcarbamoyloxymethylcephem compounds

---

SU1309911A3|1987-05-07|Method of producing 7-substituted 3-vinyl-cephalosporines as their active salts with acids

---

US4572801A|1986-02-25|4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production

---

US4104469A|1978-08-01|7-|acetamido-3-|-3-cephem-4-carboxylic acids

---

US4661590A|1987-04-28|Substituted vinyl cephalosporins

---

US4296111A|1981-10-20|7-Substituted methyl cephalosporins derivatives and analogues thereof

---

US3928336A|1975-12-23|7-{8 D-|{9 -3-|carbonylthiomethyl-3-cephem-4-carboxylic acids

---

US4673739A|1987-06-16|4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production

---

US4957912A|1990-09-18|7 acylamidocarbacephem antibacterial agents

---

US4560749A|1985-12-24|Cephem-3-imidates and 3-amidines

---

EP0066373B1|1985-03-20|Beta-lactam derivatives, a process for their preparation and compositions containing them

---

FI58332C|1981-01-12|FOERFARANDE FOER FRAMSTAELLNING AV ESTRAR AV KLAVULANSYRA

---

EP0157000A2|1985-10-09|Ester of cephalosporin derivatives

---

EP0098615B1|1988-01-07|1-oxadethiacephalosporin compound and antibacterial agent containing the same

---

KR930007414B1|1993-08-10|Intermediates for preparing cephalosporin compounds

同族专利:

---

公开号 | 公开日

---

FI840300A|1984-07-29|

---

ES535953A0|1985-10-01|

---

DE3402642C2|1989-11-09|

---

NO165027C|1990-12-12|

---

IE840026L|1984-07-28|

---

GB2135305A|1984-08-30|

---

HU191990B|1987-04-28|

---

YU14084A|1987-06-30|

---

ES529171A0|1985-05-16|

---

SE466204B|1992-01-13|

---

ES8505206A1|1985-05-16|

---

SE8400419D0|1984-01-27|

---

SE8703153D0|1987-08-13|

---

CA1233815A|1988-03-08|

---

FI840300A0|1984-01-25|

---

DK162052C|1992-02-10|

---

ES8600310A1|1985-10-01|

---

NL8400229A|1984-08-16|

---

SE8400419L|1984-07-29|

---

DD228261A5|1985-10-09|

---

SE8703153L|1987-08-13|

---

IT1218842B|1990-04-24|

---

FI881929A0|1988-04-25|

---

PT78020A|1984-02-01|

---

US4520022A|1985-05-28|

---

NO840334L|1984-07-30|

---

AU566112B2|1987-10-08|

---

GB8402255D0|1984-02-29|

---

AT383351B|1987-06-25|

---

CZ280411B6|1996-01-17|

---

NL190581B|1993-12-01|

---

DK162052B|1991-09-09|

---

FI79540C|1990-01-10|

---

OA07643A|1985-05-23|

---

IL70773A|1988-09-30|

---

DK35384A|1984-07-29|

---

DE3402642A1|1984-08-02|

---

HK73690A|1990-09-28|

---

FR2540117A1|1984-08-03|

---

DK35384D0|1984-01-26|

---

HUT34492A|1985-03-28|

---

DD222029A5|1985-05-08|

---

NL190581C|1994-05-02|

---

YU44393B|1990-06-30|

---

FI81356B|1990-06-29|

---

FR2540117B1|1987-03-20|

---

SK61684A3|1998-03-04|

---

FI81356C|1990-10-10|

---

AR240824A1|1991-02-28|

---

GR79791B|1984-10-31|

---

FI79540B|1989-09-29|

---

CA1241948A|1988-09-13|

---

FI881929A|1988-04-25|

---

BE898778A|1984-07-27|

---

CA1225084A|1987-08-04|

---

SK278845B6|1998-03-04|

---

ZW1184A1|1984-08-29|

---

ATA29984A|1986-11-15|

---

NO165027B|1990-09-03|

---

PT78020B|1986-06-02|

---

CH661731A5|1987-08-14|

---

AU2357584A|1984-08-02|

---

AR240824A2|1991-02-28|

---

LU85184A1|1984-10-24|

---

IT8419346D0|1984-01-27|

---

GB2135305B|1987-03-04|

---

IE56784B1|1991-12-18|

---

IL70773D0|1984-04-30|

---

CY1528A|1990-11-16|

---

NZ206973A|1987-03-06|

---

SE458611B|1989-04-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3507861A|1966-09-14|1970-04-21|Lilly Co Eli|Certain 3-methyl-cephalosporin compounds|

---

US3351596A|1966-09-21|1967-11-07|Lilly Co Eli|3-formyl cephalosporins|

---

CY773A|1967-09-05|1975-03-01|Bristol Myers Co|Antibacterial agents and a process for the preparation thereof|

---

US3485819A|1968-07-02|1969-12-23|Squibb & Sons Inc|Alpha-amino-cyclohexadienylalkylene-penicillins and cephalosporins|

---

US4107431A|1970-01-23|1978-08-15|Glaxo Laboratories Limited|Δ3 -3-Vinyl or substituted vinyl-4-carboxy cephalosporins|

---

US3769277A|1970-01-23|1973-10-30|Glaxo Lab Ltd|Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group|

---

US3994884A|1970-01-23|1976-11-30|Glaxo Laboratories Limited|3-Vinyl-7β--cephalosporins|

---

GB1342241A|1970-01-23|1974-01-03|Glaxo Lab Ltd|Cephalosporin compounds|

---

US3674784A|1970-07-27|1972-07-04|Lilly Co Eli|3-formyl cephalosporin sulfoxides|

---

US4065620A|1971-06-14|1977-12-27|Eli Lilly And Company|3- vinyl cephalosporins|

---

BE789817A|1971-10-07|1973-04-06|Glaxo Lab Ltd|IMPROVEMENTS WITH CEPHALOSPORIN COMPOUNDS|

---

US3925372A|1973-02-23|1975-12-09|Lilly Co Eli|Alpha-aminoacyl-3-halo cephalosporins|

---

GB1472174A|1973-09-22|1977-05-04|Beecham Group Ltd|Dihydroxy amino cephalosporins|

---

FR2264021B3|1974-03-13|1976-12-24|Aries Robert|

---

JPS5129492A|1974-09-04|1976-03-12|Sankyo Co| Sefuarosuhorinjudotai no seiho |

---

US4049806A|1975-08-15|1977-09-20|Syntex Inc.|Cephalosporin type antibacterials|

---

US3983113A|1975-08-15|1976-09-28|Syntex Inc.|Cephalosporin type antibacterials|

---

US4094978A|1976-07-29|1978-06-13|Syntex Inc.|3-propenyl derivatives of cephalosporin, compositions and their use|

---

US4112087A|1976-11-04|1978-09-05|Syntex Inc.|Cephalosporin type antibacterials having a substituted propenyl group in the 3-position|

---

US4255423A|1977-07-27|1981-03-10|Merck & Co., Inc.|Cephalosporin compounds|

---

FR2457297B1|1979-05-23|1982-10-22|Rhone Poulenc Sante|

---

US4409214A|1979-11-19|1983-10-11|Fujisawa Pharmaceutical, Co., Ltd.|7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof|ZA84584B|1983-01-28|1984-09-26|Bristol Myers Co|Substituted vinyl cephalosporins|

---

GB8411954D0|1984-05-10|1984-06-13|Glaxo Group Ltd|Cephalosporin antibiotics|

---

FR2580652B1|1985-04-22|1989-01-06|Bristol Myers Co|7-AMINO-3-PROPENYLCEPHALOSPORANIC ACID AND ITS ESTERS|

---

US4699979A|1985-04-22|1987-10-13|Bristol-Meyers Company|7-amino-3-propenylcephalosporanic acid and esters thereof|

---

US4708955A|1985-06-24|1987-11-24|Bristol-Myers Company|3-propenyl-7-aminothiazol-ylcephalosporanic acids and esters thereof|

---

US4694079A|1985-07-29|1987-09-15|Bristol-Myers Company|3-propenyl cephalosporin solvates|

---

US4619925A|1985-11-08|1986-10-28|Bristol-Myers Company|3-Propenyl cephalosporin derivatives|

---

US4727070A|1985-11-25|1988-02-23|Bristol-Myers Company|3-Propenzl cephalosporin isomer separation process and derivative|

---

US4847373A|1987-02-26|1989-07-11|Bristol-Myers Company|Production of 3-allyl- and 3-butenyl-3-cephems|

---

DE3734005A1|1987-05-26|1988-12-15|Bayer Ag|SUBSTITUTED VINYLCEPHALOSPORINS, THE METHOD OF MANUFACTURING THEIR PRODUCTS AND THEIR USE AS A MEDICINAL PRODUCT|

---

DE3734004A1|1987-05-26|1988-12-15|Bayer Ag|SUBSTITUTED VINYLCEPHALOSPORINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|

---

US5128336A|1988-03-23|1992-07-07|Eli Lilly And Company|3--1-carba-3-cephems|

---

US5245027A|1989-11-21|1993-09-14|Bristol-Myers Squibb Company|3-fluorosulfonyloxyceph-3-em compounds|

---

AT205214T|1992-02-05|2001-09-15|Biochemie Gmbh|METHOD FOR PURIFYING A 3-CEPHEM-4-CARBOXYL ACID DERIVATE|

---

JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|

---

US7230097B2|2003-03-10|2007-06-12|Lupin Ltd.|Process for preparation of 7-[α-Aminoacetamido]-3-substituted-3-cephem-4-carboxylic acid|

---

EP1638520A2|2003-06-19|2006-03-29|Ranbaxy Laboratories Limited|Solvates of cefprozil|

---

EP1678186A4|2003-10-30|2007-04-25|Cj Corp|Processes for the preparation of cephem derivatives|

---

US20070072945A1|2004-03-31|2007-03-29|Pohoreski Anton|Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake|

---

WO2006048887A1|2004-11-01|2006-05-11|Hetero Drugs Limited|A novel process for preparation of cefprozil intermediate|

---

CA2935651A1|2007-10-09|2009-04-16|Gladius Pharmaceuticals Corporation|Broad spectrum beta-lactamase inhibitors|

---

TR201000689A1|2010-01-29|2011-08-22|Bi̇lgi̇ç Mahmut|Solid dosage forms containing cefprozil.|

---

WO2013109201A1|2012-01-18|2013-07-25|Mahmut Bilgic|Pharmaceutical compositions comprising cefprozil and clavulanic acid|

---

EP3441071A1|2013-03-12|2019-02-13|Gladius Pharmaceuticals Corporation|Derivatized cephalosporins|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US46183383A| true| 1983-01-28|1983-01-28|

---

US06/564,604|US4520022A|1983-01-28|1983-12-28|Substituted vinyl cephalosporins|

---